<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RISPERDAL - risperidone tablet </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>These highlights do not include all the information needed to use RISPERDAL® safely and effectively. See full prescribing information for RISPERDAL®. RISPERDAL® (risperidone) tablets, for oral use RISPERDAL® (risperidone) oral solution RISPERDAL® M-TAB® (risperidone) orally disintegrating tablets Initial U.S. Approval: 1993</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1>BOXED WARNING</h1>
<p class="First"></p>
<p><span class="Bold">Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. RISPERDAL<span class="Sup">®</span> (risperidone) is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. <span class="Italics">[See<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span></span></p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p>RISPERDAL<span class="Sup">®</span> is an atypical antipsychotic indicated for:</p>
<ul>
<li>Treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (<a href="#S1.1">1.1</a>)</li>
<li>As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> (<a href="#S1.2">1.2</a>)</li>
<li>Treatment of <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> associated with <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span> (<a href="#S1.3">1.3</a>)</li>
</ul>
<p>
 
</p>
<p></p>
<p>RISPERDAL<span class="Sup">®</span> (risperidone) is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. Efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults <span class="Italics">[see </span><span class="Italics"><a href="#S14.1">Clinical Studies (14.1)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Monotherapy</span></p>
<p>RISPERDAL<span class="Sup">®</span> is indicated for the treatment of acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>. Efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) <span class="Italics">[see </span><span class="Italics"><a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Adjunctive Therapy</span></p>
<p>RISPERDAL<span class="Sup">®</span> adjunctive therapy with lithium or valproate is indicated for the treatment of acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>. Efficacy was established in one short-term trial in adults <span class="Italics">[see </span><span class="Italics"><a href="#S14.3">Clinical Studies (14.3)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>RISPERDAL<span class="Sup">®</span> is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> associated with <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span>, including symptoms of <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span> towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. Efficacy was established in 3 short-term trials in children and adolescents (ages 5 to 17 years)   <span class="Italics">[see </span><span class="Italics"><a href="#S14.4">Clinical Studies (14.4)</a>]</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<table width="75%">
<caption><span>Table 1. Recommended Daily Dosage by Indication</span></caption>
<col align="left" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="center" colspan="1">Initial Dose</th>
<th align="center" colspan="1">Titration (Increments)</th>
<th align="center" colspan="1">Target Dose</th>
<th align="center" colspan="1">Effective Dose Range</th>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>: adults<a href="#S2.1"> (2.1)</a></span></td>
<td align="center">2 mg<br>
</td>
<td align="center">1 to 2 mg<br>
</td>
<td align="center">4 to 8 mg</td>
<td align="center">4 to 16 mg</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span>: adolescents<a href="#S2.2"> (2.2</a></span></td>
<td align="center">0.5 mg<br>
</td>
<td align="center">0.5 to 1 mg<br>
</td>
<td align="center">3 mg<br>
</td>
<td align="center">1 to 6 mg<br>
</td>
</tr>
<tr>
<td align="left"><span class="Bold">Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>: adults<a href="#S2.2"> (2.2)</a></span></td>
<td align="center">2 to 3 mg<br>
</td>
<td align="center">1 mg</td>
<td align="center">1 to 6 mg</td>
<td align="center">1 to 6 mg<br>
</td>
</tr>
<tr>
<td align="left"><span class="Bold">Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>: children and<br>adolescents<a href="#S2.2"> (2.2)</a></span></td>
<td align="center">0.5 mg<br>
</td>
<td align="center">0.5 to 1 mg<br>
</td>
<td align="center">1 to 2.5 mg<br>
</td>
<td align="center">1 to 6 mg<br>
</td>
</tr>
<tr class="Last">
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span> in <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span><a href="#S2.3"> (2.3)</a></span></td>
<td align="center">0.25 mg<br>Can increase to<br>0.5 mg by Day 4:<br>(body weight less than 20 kg)<br><br>0.5 mg<br>Can increase to<br>1 mg by Day 4:<br>(body weight greater than or equal to 20 kg)</td>
<td align="center">After Day 4, at intervals of  &gt; 2 weeks:<br>0.25 mg<br>(body weight less than 20 kg)<br><br>0.5 mg<br>(body weight greater than or equal to 20 kg)<br>
</td>
<td align="center">0.5 mg:<br>(body weight less than 20 kg)<br><br>1 mg:<br>(body weight greater than or equal to 20 kg)</td>
<td align="center">0.5 to 3 mg</td>
</tr>
</tbody>
</table>
<p>Severe Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> in Adults: use a lower starting dose of 0.5 mg twice daily. May increase to dosages above 1.5 mg twice daily at intervals of at one week or longer.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Adults</span></p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Usual Initial Dose</span></p>
<p>RISPERDAL<span class="Sup">®</span> can be administered once or twice daily. Initial dosing is 2 mg per day. May increase the dose at intervals of 24 hours or greater, in increments of 1 to 2 mg per day, as tolerated, to a recommended dose of 4 to 8 mg per day. In some patients, slower titration may be appropriate. Efficacy has been demonstrated in a range of 4 mg to 16 mg per day. However, doses above 6 mg per day for twice daily dosing were not demonstrated to be more efficacious than lower doses, were associated with more <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> and other adverse effects, and are generally not recommended. In a single study supporting once-daily dosing, the efficacy results were generally stronger for 8 mg than for 4 mg. The safety of doses above 16 mg per day has not been evaluated in clinical trials <span class="Italics">[see<a href="#S14.1"> Clinical Studies (14.1)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Adolescents</span></p>
<p>The initial dose is 0.5 mg once daily, administered as a single-daily dose in the morning or evening. The dose may be adjusted at intervals of 24 hours or greater, in increments of 0.5 mg or 1 mg per day, as tolerated, to a recommended dose of 3 mg per day. Although efficacy has been demonstrated in studies of adolescent patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> at doses between 1 mg to 6 mg per day, no additional benefit was observed above 3 mg per day, and higher doses were associated with more adverse events. Doses higher than 6 mg per day have not been studied.</p>
<p>Patients experiencing persistent <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> may benefit from administering half the daily dose twice daily.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Maintenance Therapy</span></p>
<p>While it is unknown how long a patient with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> should remain on RISPERDAL<span class="Sup">®</span>, the effectiveness of RISPERDAL<span class="Sup">®</span> 2 mg per day to 8 mg per day at delaying relapse was demonstrated in a controlled trial in adult patients who had been clinically stable for at least 4 weeks and were then followed for a period of 1 to 2 years <span class="Italics">[see </span><span class="Italics"><a href="#S14">Clinical Studies (14.1)</a>]</span>. Both adult and adolescent patients who respond acutely should generally be maintained on their effective dose beyond the acute episode. Patients should be periodically reassessed to determine the need for maintenance treatment.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Reinitiation of Treatment in Patients Previously Discontinued</span></p>
<p>Although there are no data to specifically address reinitiation of treatment, it is recommended that after an interval off RISPERDAL<span class="Sup">®</span>, the initial titration schedule should be followed.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Switching From Other Antipsychotics</span></p>
<p>There are no systematically collected data to specifically address switching schizophrenic patients from other antipsychotics to RISPERDAL<span class="Sup">®</span>, or treating patients with concomitant antipsychotics.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Usual Dose</span></p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Adults</span></p>
<p>The initial dose range is 2 mg to 3 mg per day. The dose may be adjusted at intervals of 24 hours or greater, in increments of 1 mg per day. The effective dose range is 1 mg to 6 mg per day, as studied in the short-term, placebo-controlled trials. In these trials, short-term (3 week) anti-<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> efficacy was demonstrated in a flexible dosage range of 1 mg to 6 mg per day <span class="Italics">[see </span><span class="Italics"><a href="#S14.2">Clinical Studies (14.2</a></span>, <span class="Italics"><a href="#S14.3">14.3)</a>]</span>. RISPERDAL<span class="Sup">®</span> doses higher than 6 mg per day were not studied.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Pediatrics</span></p>
<p>The initial dose is 0.5 mg once daily, administered as a single-daily dose in the morning or evening. The dose may be adjusted at intervals of 24 hours or greater, in increments of 0.5 mg or 1 mg per day, as tolerated, to the recommended target dose of 1 mg to 2.5 mg per day. Although efficacy has been demonstrated in studies of pediatric patients with bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> at doses between 0.5 mg and 6 mg per day, no additional benefit was observed above 2.5 mg per day, and higher doses were associated with more adverse events. Doses higher than 6 mg per day have not been studied.</p>
<p>Patients experiencing persistent <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> may benefit from administering half the daily dose twice daily.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Maintenance Therapy</span></p>
<p>There is no body of evidence available from controlled trials to guide a clinician in the longer-term management of a patient who improves during treatment of an acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episode</span> with RISPERDAL<span class="Sup">®</span>. While it is generally agreed that pharmacological treatment beyond an acute response in <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> is desirable, both for maintenance of the initial response and for prevention of new <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episodes</span>, there are no systematically obtained data to support the use of RISPERDAL<span class="Sup">®</span> in such longer-term treatment (i.e., beyond 3 weeks). The physician who elects to use RISPERDAL<span class="Sup">®</span> for extended periods should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient.</p>
<p>
 
</p>
<p></p>
<p>The dosage of RISPERDAL<span class="Sup">®</span> should be individualized according to the response and tolerability of the patient. The total daily dose of RISPERDAL<span class="Sup">®</span> can be administered once daily, or half the total daily dose can be administered twice daily.</p>
<p>For patients with body weight less than 20 kg, initiate dosing at 0.25 mg per day. For patients with body weight greater than or equal to 20 kg, initiate dosing at 0.5 mg per day. After a minimum of four days, the dose may be increased to the recommended dose of 0.5 mg per day for patients less than 20 kg and 1.0 mg per day for patients greater than or equal to 20 kg. Maintain this dose for a minimum of 14 days. In patients not achieving sufficient clinical response, the dose may be increased at intervals of 2 weeks or greater, in increments of 0.25 mg per day for patients less than 20 kg, or increments of 0.5 mg per day for patients greater than or equal to 20 kg. The effective dose range is 0.5 mg to 3 mg per day. No dosing data are available for children who weigh less than 15 kg.</p>
<p>Once sufficient clinical response has been achieved and maintained, consider gradually lowering the dose to achieve the optimal balance of efficacy and safety. The physician who elects to use RISPERDAL<span class="Sup">®</span> for extended periods should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient.</p>
<p>Patients experiencing persistent <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> may benefit from a once-daily dose administered at bedtime or administering half the daily dose twice daily, or a reduction of the dose.</p>
<p>
 
</p>
<p></p>
<p>For patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CLcr &lt; 30 mL/min) or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (10–15 points on Child Pugh System), the initial starting dose is 0.5 mg twice daily. The dose may be increased in increments of 0.5 mg or less, administered twice daily. For doses above 1.5 mg twice daily, increase in intervals of one week or greater <span class="Italics">[see<a href="#S8.6"> Use in Specific Populations (8.6 </a></span><span class="Italics">and<a href="#S8.7"> 8.7)</a>].</span></p>
<p>
 
</p>
<p></p>
<p>When RISPERDAL<span class="Sup">®</span> is co-administered with enzyme inducers (e.g., carbamazepine), the dose of RISPERDAL<span class="Sup">®</span> should be increased up to double the patient's usual dose. It may be necessary to decrease the RISPERDAL<span class="Sup">®</span> dose when enzyme inducers such as carbamazepine are discontinued <span class="Italics">[see </span><span class="Italics"><a href="#S7.1">Drug Interactions (7.1)</a>]</span>. Similar effect may be expected with co-administration of RISPERDAL<span class="Sup">® </span>with other enzyme inducers (e.g., phenytoin, rifampin, and phenobarbital).</p>
<p>When fluoxetine or paroxetine is co-administered with RISPERDAL<span class="Sup">®</span>, the dose of RISPERDAL<span class="Sup">®</span> should be reduced. The RISPERDAL<span class="Sup">®</span> dose should not exceed 8 mg per day in adults when co-administered with these drugs. When initiating therapy, RISPERDAL<span class="Sup">®</span> should be titrated slowly. It may be necessary to increase the RISPERDAL<span class="Sup">®</span> dose when enzyme inhibitors such as fluoxetine or paroxetine are discontinued <span class="Italics">[see </span><span class="Italics"><a href="#S7.1">Drug Interactions (7.1)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>RISPERDAL<span class="Sup">®</span> Oral Solution can be administered directly from the calibrated pipette, or can be mixed with a beverage prior to administration. RISPERDAL<span class="Sup">®</span> Oral Solution is compatible in the following beverages: water, coffee, orange juice, and low-fat milk; it is NOT compatible with either cola or tea.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Tablet Accessing</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics">RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablets 0.5 mg, 1 mg, and 2 mg</span></p>
<p>RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablets 0.5 mg, 1 mg, and 2 mg are supplied in <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs of 4 tablets each.</p>
<p>Do not open the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> until ready to administer. For single tablet removal, separate one of the four <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> units by tearing apart at the perforations. Bend the corner where indicated. Peel back foil to expose the tablet. DO NOT push the tablet through the foil because this could damage the tablet.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablets 3 mg and 4 mg</span></p>
<p>RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablets 3 mg and 4 mg are supplied in a child-resistant pouch containing a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> with 1 tablet each.</p>
<p>The child-resistant pouch should be torn open at the notch to access the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>. Do not open the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> until ready to administer. Peel back foil from the side to expose the tablet. DO NOT push the tablet through the foil, because this could damage the tablet.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Tablet Administration</span></p>
<p>Using dry hands, remove the tablet from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> unit and immediately place the entire RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablet on the tongue. The RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablet should be consumed immediately, as the tablet cannot be stored once removed from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> unit. RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablets disintegrate in the mouth within seconds and can be swallowed subsequently with or without liquid. Patients should not attempt to split or to chew the tablet.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>DOSAGE FORMS &amp; STRENGTHS</h1>
<p class="First"></p>
<p>RISPERDAL<span class="Sup">®</span> Tablets are available in the following strengths and colors: 0.25 mg (dark yellow), 0.5 mg (red-brown), 1 mg (white), 2 mg (orange), 3 mg (yellow), and 4 mg (green). All are capsule shaped, and imprinted with "JANSSEN" on one side and either "Ris 0.25", "Ris 0.5", "R1", "R2", "R3", or "R4" on the other side according to their respective strengths.</p>
<p>RISPERDAL<span class="Sup">®</span> Oral Solution is available in a 1 mg/mL strength.</p>
<p>RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablets are available in the following strengths, colors, and shapes: 0.5 mg (light coral, round), 1 mg (light coral, square), 2 mg (coral, square), 3 mg (coral, round), and 4 mg (coral, round). All are biconvex and etched on one side with "R0.5", "R1", "R2", "R3", or "R4" according to their respective strengths.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p>RISPERDAL<span class="Sup">®</span> is contraindicated in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to RISPERDAL<span class="Sup">®</span>. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> and <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, have been observed in patients treated with risperidone.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>WARNINGS AND PRECAUTIONS</h1>
<p class="First"></p>
<ul>
<li>Cerebrovascular events, including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>: RISPERDAL<span class="Sup">®</span> is not approved for use in patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. (<a href="#S5.2">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span>: Manage with immediate discontinuation of RISPERDAL<span class="Sup">®</span> and close monitoring. (<a href="#S5.3">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive dyskinesia</span>: Consider discontinuing RISPERDAL<span class="Sup">®</span> if clinically indicated. (<a href="#S5.4">5.4</a>)</li>
<li>Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/ cerebrovascular risk. These metabolic changes include <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. (<a href="#S5.5">5.5</a>)<ul>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus:</span> Monitor patients for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Monitor glucose regularly in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or at risk for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. (<a href="#S5.5">5.5</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>:</span> Undesirable alterations have been observed in patients treated with atypical antipsychotics. (<a href="#S5.5">5.5</a>)</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span>:</span> Significant <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> has been reported. Monitor <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. (<a href="#S5.5">5.5</a>)</li>
</ul>
</li>
<li><span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span>: Prolactin elevations occur and persist during chronic administration. (<a href="#S5.6">5.6</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span>: For patients at risk, consider a lower starting dose and slower titration. (<a href="#S5.7">5.7</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>: Perform complete blood counts in patients with a history of clinically significant low white blood cell count (WBC). Consider discontinuing RISPERDAL if a clinically significant decline in WBC occurs in the absence of other causative factors. (<a href="#S5.8">5.8</a>)</li>
<li>Potential for cognitive and motor impairment: Use caution when operating machinery. (<a href="#S5.9">5.9</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>: Use cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or with conditions that lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold. (<a href="#S5.10">5.10</a>)</li>
</ul>
<p>
 
</p>
<p></p>
<p>Elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> treated with antipsychotic drugs are at an increased risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients of between 1.6 to 1.7 times the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were varied, most of the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> appeared to be either cardiovascular (e.g., <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>) or infectious (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>) in nature. Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.</p>
<p>In two of four placebo-controlled trials in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, a higher incidence of mortality was observed in patients treated with furosemide plus RISPERDAL<span class="Sup">®</span> when compared to patients treated with RISPERDAL<span class="Sup">®</span> alone or with placebo plus furosemide. No pathological mechanism has been identified to explain this finding, and no consistent pattern for cause of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was observed.</p>
<p>RISPERDAL<span class="Sup">®</span> (risperidone) is not approved for the treatment of <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see<a href="#BOX"> Boxed Warning</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>Cerebrovascular adverse reactions (e.g., <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, transient ischemic attack), including fatalities, were reported in patients (mean age 85 years; range 73–97) in trials of risperidone in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. In placebo-controlled trials, there was a significantly higher incidence of cerebrovascular adverse events in patients treated with risperidone compared to patients treated with placebo. RISPERDAL<span class="Sup">®</span> is not approved for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>. <span class="Italics">[see</span><span class="Italics"><a href="#BOX"> Boxed Warning </a></span><span class="Italics">and </span><span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a>] </span></p>
<p>
 
</p>
<p></p>
<p>Antipsychotic drugs including RISPERDAL<span class="Sup">®</span> can cause a potentially fatal symptom complex  referred to as <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic Malignant Syndrome</span> (NMS). Clinical manifestations of NMS include <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">hyperpyrexia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, altered mental status, and <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (<span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">irregular pulse</span> or blood pressure, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase (CPK), <span class="product-label-link" type="condition" conceptid="439142" conceptname="Myoglobinuria">myoglobinuria</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.</p>
<p>The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases in which the clinical presentation includes both serious medical illness (e.g., <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, systemic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, and primary central nervous system pathology.</p>
<p>The management of NMS should include: (1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; (2) intensive symptomatic treatment and medical monitoring; and (3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.</p>
<p>If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.</p>
<p>
 
</p>
<p></p>
<p>A syndrome of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. The risk of developing <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.</p>
<p>There is no known treatment for established cases of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.</p>
<p>Given these considerations, prescribe RISPERDAL<span class="Sup">®</span> in a manner that is most likely to minimize the occurrence of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that: (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.</p>
<p>If signs and symptoms of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> appear in a patient treated with RISPERDAL<span class="Sup">®</span>, consider drug discontinuation. However, some patients may require treatment with RISPERDAL<span class="Sup">®</span> despite the presence of the syndrome.</p>
<p>
 
</p>
<p></p>
<p><span>Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, and body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile.</span></p>
<p>
 
</p>
<p></p>
<p><span class="Underline"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</span></p>
<p><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, in some cases extreme and associated with <span class="product-label-link" type="condition" conceptid="4209145" conceptname="Ketoacidosis">ketoacidosis</span> or hyperosmolar <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported in patients treated with atypical antipsychotics including RISPERDAL<span class="Sup">®</span>. Assessment of the relationship between atypical antipsychotic use and glucose abnormalities is complicated by the possibility of an increased background risk of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and the increasing incidence of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus in the general population. Given these confounders, the relationship between atypical antipsychotic use and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse events is not completely understood. However, epidemiological studies suggest an increased risk of treatment-emergent <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse events in patients treated with the atypical antipsychotics. Precise risk estimates for <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>-related adverse events in patients treated with atypical antipsychotics are not available.</p>
<p>Patients with an established diagnosis of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus who are started on atypical antipsychotics, including RISPERDAL<span class="Sup">®</span>, should be monitored regularly for worsening of glucose control. Patients with risk factors for <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus (e.g., <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, family history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are starting treatment with atypical antipsychotics, including RISPERDAL<span class="Sup">®</span>, should undergo fasting blood glucose testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics, including RISPERDAL<span class="Sup">®</span>, should be monitored for symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> including <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="438872" conceptname="Excessive eating - polyphagia">polyphagia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. Patients who develop symptoms of <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> during treatment with atypical antipsychotics, including RISPERDAL<span class="Sup">®</span>, should undergo fasting blood glucose testing. In some cases, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> has resolved when the atypical antipsychotic, including RISPERDAL<span class="Sup">®</span>, was discontinued; however, some patients required continuation of anti-diabetic treatment despite discontinuation of RISPERDAL<span class="Sup">®</span>.</p>
<p>Pooled data from three double-blind, placebo-controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> studies and four double-blind, placebo-controlled bipolar monotherapy studies are presented in Table 2.</p>
<table width="100%">
<caption><span>Table 2. Change in Random Glucose from Seven Placebo-Controlled, 3- to 8-Week, Fixed- or Flexible-Dose Studies in Adult Subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> or Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></span></caption>
<col align="left" span="1" valign="top" width="35%">
<col align="center" span="1" valign="top" width="15%">
<col align="center" span="1" valign="top" width="35%">
<col align="center" span="1" valign="top" width="15%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="center" colspan="1"></th>
<th align="center" colspan="2">                 RISPERDAL<span class="Sup">®</span>
</th>
</tr>
<tr>
<th align="left" colspan="1"></th>
<th align="center" colspan="1">Placebo</th>
<th align="center" colspan="1">1–8 mg/day</th>
<th align="center" colspan="1">&gt;8–16 mg/day</th>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">Mean change from baseline (mg/dL)</span></td>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">n=555</span></td>
<td align="center"><span class="Bold">n=748</span></td>
<td align="center"><span class="Bold">n=164</span></td>
</tr>
<tr>
<td align="left">Serum Glucose</td>
<td align="center">-1.4</td>
<td align="center">0.8</td>
<td align="center">0.6</td>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">Proportion of patients with shifts</span></td>
</tr>
<tr class="Last">
<td align="left">Serum Glucose<br>(&lt;140 mg/dL to ≥200 mg/dL)</td>
<td align="center">0.6%<br>(3/525)</td>
<td align="center">0.4%<br>(3/702)</td>
<td align="center">0%<br>(0/158)</td>
</tr>
</tbody>
</table>
<p>In longer-term, controlled and uncontrolled studies, RISPERDAL<span class="Sup">®</span> was associated with a mean change in glucose of +2.8 mg/dL at Week 24 (n=151) and +4.1 mg/dL at Week 48 (n=50).</p>
<p><span>Data from the placebo-controlled 3- to 6-week study in children and adolescents with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (13–17 years of age), bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> (10–17 years of age), or <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span> (5 to 17 years of age) are presented in Table 3.</span></p>
<table width="100%">
<caption><span>Table 3. Change in Fasting Glucose from Three Placebo-Controlled, 3- to 6-Week, Fixed-Dose Studies in Children and Adolescents with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> (13–17 years of age), Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> (10–17 years of age), or <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">Autistic Disorder</span> (5 to 17 years of age)</span></caption>
<col align="left" span="1" valign="top" width="33%">
<col align="center" span="1" valign="top" width="34%">
<col align="center" span="1" valign="top" width="33%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="center" colspan="1"></th>
<th align="center" colspan="1">RISPERDAL<span class="Sup">®</span>
</th>
</tr>
<tr>
<th align="left" colspan="1"></th>
<th align="center" colspan="1">Placebo</th>
<th align="center" colspan="1">0.5–6 mg/day</th>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">Mean change from baseline (mg/dL)</span></td>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">n=76</span></td>
<td align="center"><span class="Bold">n=135</span></td>
</tr>
<tr>
<td align="left">Serum Glucose</td>
<td align="center">-1.3</td>
<td align="center">2.6</td>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">Proportion of patients with shifts</span></td>
</tr>
<tr>
<td align="left">
<br>Serum Glucose<br>(&lt;100 mg/dL to ≥126 mg/dL)</td>
<td align="center">
<br>0%</td>
<td align="center">
<br>0.8%</td>
</tr>
<tr><td align="left"></td></tr>
<tr>
<td align="left"></td>
<td align="center">(0/64)</td>
<td align="center">(1/120)</td>
</tr>
<tr class="Last"><td align="left"></td></tr>
</tbody>
</table>
<p>In longer-term, uncontrolled, open-label extension pediatric studies, RISPERDAL<span class="Sup">®</span> was associated with a mean change in fasting glucose of +5.2 mg/dL at Week 24 (n=119).</p>
<p>
 
</p>
<p></p>
<p><span><span class="Underline"><span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span></span></span></p>
<p><span>Undesirable alterations in lipids have been observed in patients treated with atypical antipsychotics.</span></p>
<p>Pooled data from 7 placebo-controlled, 3- to 8- week, fixed- or flexible-dose studies in adult subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> are presented in Table 4.</p>
<table width="100%">
<caption><span>Table 4. Change in Random Lipids from Seven Placebo-Controlled, 3- to 8-Week, Fixed- or Flexible-Dose Studies in Adult Subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> or Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></span></caption>
<col align="left" span="1" valign="top" width="35%">
<col align="center" span="1" valign="top" width="15%">
<col align="center" span="1" valign="top" width="35%">
<col align="center" span="1" valign="top" width="15%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="center" colspan="1"></th>
<th align="center" colspan="2">RISPERDAL<span class="Sup">®</span>
</th>
</tr>
<tr>
<th align="left" colspan="1"></th>
<th align="center" colspan="1">Placebo</th>
<th align="center" colspan="1">1–8 mg/day</th>
<th align="center" colspan="1">&gt;8–16 mg/day</th>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">Mean change from baseline (mg/dL)</span></td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></span></td>
<td align="center"><span class="Bold">n=559</span></td>
<td align="center"><span class="Bold">n=742</span></td>
<td align="center"><span class="Bold">n=156</span></td>
</tr>
<tr>
<td align="left">Change from baseline</td>
<td align="center">0.6</td>
<td align="center">6.9</td>
<td align="center">1.8</td>
</tr>
<tr>
<td align="left"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="Bold">Triglycerides</span></td>
<td align="center"><span class="Bold">n=183</span></td>
<td align="center"><span class="Bold">n=307</span></td>
<td align="center"><span class="Bold">n=123</span></td>
</tr>
<tr>
<td align="left">Change from baseline</td>
<td align="center">-17.4</td>
<td align="center">-4.9</td>
<td align="center">-8.3</td>
</tr>
<tr>
<td align="left"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">Proportion of patients With Shifts</span></td>
</tr>
<tr>
<td align="left">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></span><br>(&lt;200 mg/dL to ≥240 mg/dL)</td>
<td align="center">2.7%</td>
<td align="center">4.3%</td>
<td align="center">6.3%</td>
</tr>
<tr>
<td align="left"></td>
<td align="center">(10/368)</td>
<td align="center">(22/516)</td>
<td align="center">(6/96)</td>
</tr>
<tr>
<td align="left">
<span class="Bold">Triglycerides</span><br>(&lt;500 mg/dL to ≥500 mg/dL)</td>
<td align="center">1.1%<br>(2/180)</td>
<td align="center">2.7%<br>(8/301)</td>
<td align="center">2.5%<br>(3/121)</td>
</tr>
<tr class="Last"><td align="left"></td></tr>
</tbody>
</table>
<p>In longer-term, controlled and uncontrolled studies, RISPERDAL<span class="Sup">®</span> was associated with a mean change in (a) non-fasting <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> of +4.4 mg/dL at Week 24 (n=231) and +5.5 mg/dL at Week 48 (n=86); and (b) non-fasting triglycerides of +19.9 mg/dL at Week 24 (n=52).</p>
<p>Pooled data from 3 placebo-controlled, 3- to 6-week, fixed-dose studies in children and adolescents with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (13–17 years of age), bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> (10–17 years of age), or <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span> (5–17 years of age) are presented in Table 5.</p>
<table width="100%">
<caption><span>Table 5. Change in Fasting Lipids from Three Placebo-Controlled, 3- to 6-Week, Fixed-Dose Studies in Children and Adolescents with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> (13–17 Years of Age), Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> (10–17 Years of Age), or <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">Autistic Disorder</span> (5 to 17 Years of Age)</span></caption>
<col align="left" span="1" valign="top" width="33%">
<col align="center" span="1" valign="top" width="34%">
<col align="center" span="1" valign="top" width="33%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="center" colspan="1"></th>
<th align="center" colspan="1">RISPERDAL<span class="Sup">®</span>
</th>
</tr>
<tr>
<th align="left" colspan="1"></th>
<th align="center" colspan="1">Placebo</th>
<th align="center" colspan="1">0.5–6 mg/day</th>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">Mean change from baseline (mg/dL)</span></td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></span></td>
<td align="center"><span class="Bold">n=74</span></td>
<td align="center"><span class="Bold">n=133</span></td>
</tr>
<tr>
<td align="left">Change from baseline</td>
<td align="center">0.3</td>
<td align="center">-0.3</td>
</tr>
<tr>
<td align="left"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="Bold">LDL</span></td>
<td align="center"><span class="Bold">n=22</span></td>
<td align="center"><span class="Bold">n=22</span></td>
</tr>
<tr>
<td align="left">Change from baseline</td>
<td align="center">3.7</td>
<td align="center">0.5</td>
</tr>
<tr>
<td align="left"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="Bold">HDL</span></td>
<td align="center"><span class="Bold">n=22</span></td>
<td align="center"><span class="Bold">n=22</span></td>
</tr>
<tr>
<td align="left">Change from baseline</td>
<td align="center">1.6</td>
<td align="center">-1.9</td>
</tr>
<tr>
<td align="left"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="Bold">Triglycerides</span></td>
<td align="center"><span class="Bold">n=77</span></td>
<td align="center"><span class="Bold">n=138</span></td>
</tr>
<tr>
<td align="left">Change from baseline</td>
<td align="center">-9.0</td>
<td align="center">-2.6</td>
</tr>
<tr>
<td align="left"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"></td>
<td align="center"><span class="Bold">Proportion of patients with shifts</span></td>
</tr>
<tr>
<td align="left">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></span><br>(&lt;170 mg/dL to ≥200 mg/dL)</td>
<td align="center">2.4%<br>(1/42)</td>
<td align="center">3.8%<br>(3/80)</td>
</tr>
<tr>
<td align="left">
<span class="Bold">LDL</span><br>(&lt;110 mg/dL to ≥130 mg/dL)</td>
<td align="center">0%<br>(0/16)</td>
<td align="center">0%<br>(0/16)</td>
</tr>
<tr>
<td align="left">
<span class="Bold">HDL</span><br>(≥40 mg/dL to &lt;40 mg/dL)</td>
<td align="center">0%<br>(0/19)</td>
<td align="center">10%<br>(2/20)</td>
</tr>
<tr>
<td align="left">
<span class="Bold">Triglycerides</span><br>(&lt;150 mg/dL to ≥200 mg/dL)</td>
<td align="center">1.5%<br>(1/65)</td>
<td align="center">7.1%<br>(8/113)</td>
</tr>
<tr class="Last"><td align="left"></td></tr>
</tbody>
</table>
<p>In longer-term, uncontrolled, open-label extension pediatric studies, RISPERDAL<span class="Sup">®</span> was associated with a mean change in (a) fasting <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> of +2.1 mg/dL at Week 24 (n=114); (b) fasting LDL of -0.2 mg/dL at Week 24 (n=103); (c) fasting HDL of +0.4 mg/dL at Week 24 (n=103); and (d) fasting triglycerides of +6.8 mg/dL at Week 24 (n=120).</p>
<p>
 
</p>
<p></p>
<p><span><span class="Underline"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span></span></p>
<p><span><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> has been observed with atypical antipsychotic use. Clinical monitoring of weight is recommended.</span></p>
<p>Data on mean changes in body weight and the proportion of subjects meeting a <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> criterion of 7% or greater of body weight from 7 placebo-controlled, 3- to 8- week, fixed- or flexible-dose studies in adult subjects with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> or bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> are presented in Table 6.</p>
<table width="100%">
<caption><span>Table 6. Mean Change in Body Weight (kg) and the Proportion of Subjects with ≥7% Gain in Body Weight From Seven Placebo-Controlled, 3- to 8-Week, Fixed- or Flexible-Dose Studies in Adult Subjects With <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> or Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></span></caption>
<col align="left" span="1" valign="top" width="25%">
<col align="center" span="1" valign="top" width="25%">
<col align="center" span="1" valign="top" width="25%">
<col align="center" span="1" valign="top" width="25%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="center" colspan="1"></th>
<th align="center" colspan="2">RISPERDAL<span class="Sup">®</span>
</th>
</tr>
<tr>
<th align="left" colspan="1"></th>
<th align="center" colspan="1">Placebo<br>(n=597)</th>
<th align="center" colspan="1">1–8 mg/day<br>(n=769)</th>
<th align="center" colspan="1">&gt;8–16 mg/day<br>(n=158)</th>
</tr>
<tr>
<td align="left"><span class="Bold">Weight (kg)</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">Change from baseline</td>
<td align="center">-0.3</td>
<td align="center">0.7</td>
<td align="center">2.2</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">≥7% increase from baseline</td>
<td align="center">2.9%</td>
<td align="center">8.7%</td>
<td align="center">20.9%</td>
</tr>
<tr class="Last"><td align="left"></td></tr>
</tbody>
</table>
<p>In longer-term, controlled and uncontrolled studies, RISPERDAL<span class="Sup">®</span> was associated with a mean change in weight of +4.3 kg at Week 24 (n=395) and +5.3 kg at Week 48 (n=203).</p>
<p>Data on mean changes in body weight and the proportion of subjects meeting the criterion of ≥7% gain in body weight from nine placebo-controlled, 3- to 8-week, fixed-dose studies in children and adolescents with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> (13–17 years of age), bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> (10–17 years of age), <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span> (5–17 years of age), or other psychiatric disorders (5–17 years of age) are presented in Table 7.</p>
<table width="100%">
<caption><span>Table 7. Mean Change in Body Weight (kg) and the Proportion of Subjects With ≥7% Gain in Body Weight From Nine Placebo-Controlled, 3- to 8-Week, Fixed-Dose Studies in Children and Adolescents With <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> (13–17 Years of Age), Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> (10–17 Years of Age), <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">Autistic Disorder</span> (5 to 17 Years of Age) or Other Psychiatric Disorders (5–17 Years of Age)</span></caption>
<col align="left" span="1" valign="top" width="40%">
<col align="center" span="1" valign="top" width="30%">
<col align="center" span="1" valign="top" width="30%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="center" colspan="1">Placebo<br>(n=375)</th>
<th align="center" colspan="1">RISPERDAL<span class="Sup">®</span> 0.5–6 mg/day<br>(n=448)</th>
</tr>
<tr>
<td align="left"><span class="Bold">Weight (kg)</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">Change from baseline</td>
<td align="center">0.6</td>
<td align="center">2.0</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">≥7% increase from baseline</td>
<td align="center">6.9%</td>
<td align="center">32.6%</td>
</tr>
</tbody>
</table>
<p>In longer-term, uncontrolled, open-label extension pediatric studies, RISPERDAL<span class="Sup">®</span> was associated with a mean change in weight of +5.5 kg at Week 24 (n=748) and +8.0 kg at Week 48 (n=242).</p>
<p>In a long-term, open-label extension study in adolescent patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span> was reported as a treatment-emergent adverse event in 14% of patients. In 103 adolescent patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, a mean increase of 9.0 kg was observed after 8 months of RISPERDAL<span class="Sup">®</span> treatment. The majority of that increase was observed within the first 6 months. The average percentiles at baseline and 8 months, respectively, were 56 and 72 for weight, 55 and 58 for height, and 51 and 71 for body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index.</p>
<p>In long-term, open-label trials (studies in patients with <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span> or other psychiatric disorders), a mean increase of 7.5 kg after 12 months of RISPERDAL<span class="Sup">®</span> treatment was observed, which was higher than the expected normal <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> (approximately 3 to 3.5 kg per year adjusted for age, based on Centers for Disease Control and Prevention normative data). The majority of that increase occurred within the first 6 months of exposure to RISPERDAL<span class="Sup">®</span>. The average percentiles at baseline and 12 months, respectively, were 49 and 60 for weight, 48 and 53 for height, and 50 and 62 for body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index.</p>
<p>In one 3-week, placebo-controlled trial in children and adolescent patients with acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>, increases in body weight were higher in the RISPERDAL<span class="Sup">®</span> groups than the placebo group, but not dose related (1.90 kg in the RISPERDAL<span class="Sup">®</span> 0.5–2.5 mg group, 1.44 kg in the RISPERDAL<span class="Sup">®</span> 3–6 mg group, and 0.65 kg in the placebo group). A similar trend was observed in the mean change from baseline in body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index.</p>
<p>When treating pediatric patients with RISPERDAL<span class="Sup">®</span> for any indication, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> should be assessed against that expected with normal growth.</p>
<p>
 
</p>
<p></p>
<p>As with other drugs that antagonize dopamine D<span class="Sub">2</span> receptors, RISPERDAL<span class="Sup">®</span> elevates prolactin levels and the elevation persists during chronic administration. RISPERDAL<span class="Sup">®</span> is associated with higher levels of prolactin elevation than other antipsychotic agents.</p>
<p><span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span> may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotropin secretion. This, in turn, may inhibit reproductive function by impairing gonadal steroidogenesis in both female and male patients. <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">Galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span> have been reported in patients receiving prolactin-elevating compounds. Long-standing <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span> when associated with <span class="product-label-link" type="condition" conceptid="4167354" conceptname="Hypogonadism">hypogonadism</span> may lead to decreased bone density in both female and male subjects.</p>
<p>Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin dependent <span class="Italics">in vitro</span>, a factor of potential importance if the prescription of these drugs is contemplated in a patient with previously detected breast cancer. An increase in pituitary gland, mammary gland, and pancreatic islet cell neoplasia (mammary adenocarcinomas, pituitary and <span class="product-label-link" type="condition" conceptid="4243445" conceptname="Benign neoplasm of pancreas">pancreatic adenomas</span>) was observed in the risperidone carcinogenicity studies conducted in mice and rats <span class="Italics">[see </span><span class="Italics"><a href="#S13.1">Nonclinical Toxicology (13.1)</a>]</span>. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of this class of drugs and tumorigenesis in humans; the available evidence is considered too limited to be conclusive at this time.</p>
<p>
 
</p>
<p></p>
<p>RISPERDAL<span class="Sup">®</span> may induce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> associated with <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, and in some patients, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, especially during the initial dose-titration period, probably reflecting its alpha-adrenergic antagonistic properties. <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span> was reported in 0.2% (6/2607) of RISPERDAL<span class="Sup">®</span>-treated patients in Phase 2 and 3 studies in adults with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. The risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> may be minimized by limiting the initial dose to 2 mg total (either once daily or 1 mg twice daily) in normal adults and 0.5 mg twice daily in the elderly and patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <span class="Italics">[see </span><span class="Italics"><a href="#S2.1">Dosage and Administration (2.1</a></span>,<span class="Italics"><a href="#S2.4"> 2.4)</a>]</span>. Monitoring of orthostatic vital signs should be considered in patients for whom this is of concern. A dose reduction should be considered if <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs. RISPERDAL<span class="Sup">®</span> should be used with particular caution in patients with known cardiovascular disease (history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, e.g., <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> and <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span>. Clinically significant <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> has been observed with concomitant use of RISPERDAL<span class="Sup">®</span> and antihypertensive medication.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Class Effect:</span> In clinical trial and/or postmarketing experience, events of <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> have been reported temporally related to antipsychotic agents, including RISPERDAL<span class="Sup">®</span>. <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> has also been reported.</p>
<p>Possible risk factors for <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> include pre-existing low white blood cell count (WBC) and history of drug-induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>. Patients with a history of a clinically significant low WBC or a drug-induced <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of RISPERDAL<span class="Sup">®</span> should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.</p>
<p>Patients with clinically significant <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> should be carefully monitored for <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or other symptoms or signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and treated promptly if such symptoms or signs occur. Patients with severe <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (absolute neutrophil count &lt;1000/mm3) should discontinue RISPERDAL<span class="Sup">®</span> and have their WBC followed until recovery.</p>
<p>
 
</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> was a commonly reported adverse reaction associated with RISPERDAL<span class="Sup">®</span> treatment, especially when ascertained by direct questioning of patients. This adverse reaction is dose-related, and in a study utilizing a checklist to detect adverse events, 41% of the high-dose patients (RISPERDAL<span class="Sup">®</span> 16 mg/day) reported <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> compared to 16% of placebo patients. Direct questioning is more sensitive for detecting adverse events than spontaneous reporting, by which 8% of RISPERDAL<span class="Sup">®</span> 16 mg/day patients and 1% of placebo patients reported <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> as an adverse reaction. Since RISPERDAL<span class="Sup">®</span> has the potential to impair judgment, thinking, or motor skills, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that RISPERDAL<span class="Sup">®</span> therapy does not affect them adversely.</p>
<p>
 
</p>
<p></p>
<p>During premarketing testing in adult patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> occurred in 0.3% (9/2607) of RISPERDAL<span class="Sup">®</span>-treated patients, two in association with <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>. RISPERDAL<span class="Sup">®</span> should be used cautiously in patients with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p>
 
</p>
<p></p>
<p>Esophageal dysmotility and <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span> have been associated with antipsychotic drug use. <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">Aspiration pneumonia</span> is a common cause of morbidity and mortality in patients with advanced Alzheimer's <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. RISPERDAL<span class="Sup">®</span> and other antipsychotic drugs should be used cautiously in patients at risk for <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">aspiration pneumonia</span>. <span class="Italics">[see</span><span class="Italics"><a href="#BOX"> Boxed Warning </a>and<a href="#S5.1"> Warnings and Precautions (5.1)</a>]</span></p>
<p>
 
</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span> has been reported during postmarketing surveillance. Severe <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> may require <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span>.</p>
<p>
 
</p>
<p></p>
<p>Disruption of body temperature regulation has been attributed to antipsychotic agents. Both <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span> and <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span> have been reported in association with oral RISPERDAL<span class="Sup">®</span> use. Caution is advised when prescribing for patients who will be exposed to temperature extremes.</p>
<p>
 
</p>
<p></p>
<p>Inform patients that RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablets contain phenylalanine<span class="Bold">. </span>Phenylalanine is a component of aspartame. Each 4 mg RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablet contains 0.84 mg phenylalanine; each 3 mg RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablet contains 0.63 mg phenylalanine; each 2 mg RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablet contains 0.42 mg phenylalanine; each 1 mg RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablet contains 0.28 mg phenylalanine; and each 0.5 mg RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablet contains 0.14 mg phenylalanine.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p>The following are discussed in more detail in other sections of the labeling:</p>
<ul>
<li>Increased mortality in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see </span><span class="Italics"><a href="#BOX">Boxed Warning </a></span><span class="Italics">and </span><span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li>Cerebrovascular adverse events, including <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, in elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>-related <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> <span class="Italics">[see </span><span class="Italics"><a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">Neuroleptic malignant syndrome</span> <span class="Italics">[see </span><span class="Italics"><a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive dyskinesia</span> <span class="Italics">[see </span><span class="Italics"><a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>
</li>
<li>Metabolic Changes (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">Dyslipidemia</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span>) <span class="Italics">[see </span><span class="Italics"><a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span> <span class="Italics">[see </span><span class="Italics"><a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> <span class="Italics">[see </span><span class="Italics"><a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> <span class="Italics">[see<a href="#S5.8"> Warnings and Precautions (5.8)</a>]</span>
</li>
<li>Potential for cognitive and motor impairment <span class="Italics">[see<a href="#S5.9"> Warnings and Precautions (5.9)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> <span class="Italics">[see </span><span class="Italics"><a href="#S5.10">Warnings and Precautions (5.10)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span> <span class="Italics">[see </span><span class="Italics"><a href="#S5.11">Warnings and Precautions (5.11)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span> <span class="Italics">[see </span><span class="Italics"><a href="#S5.12">Warnings and Precautions (5.12)</a>]</span>
</li>
<li>Disruption of body temperature regulation <span class="Italics">[see </span><span class="Italics"><a href="#S5.13">Warnings and Precautions (5.13)</a>]</span>
</li>
<li>Patients with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">Phenylketonuria</span> <span class="Italics">[see </span><span class="Italics"><a href="#S5.14">Warnings and Precautions (5.14)</a>].</span>
</li>
</ul>
<p>The most common adverse reactions in clinical trials (&gt;5% and twice placebo) were <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, sedation, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">upper abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">stomach discomfort</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivary hypersecretion</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">increased appetite</span>, increased weight, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">nasopharyngitis</span>, and pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p>The most common adverse reactions that were associated with discontinuation from clinical trials (causing discontinuation in &gt;1% of adults and/or &gt;2% of pediatrics) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, sedation, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> <span class="Italics">[see </span><span class="Italics"><a href="#S6.1">Adverse Reactions, Discontinuations Due to Adverse Reactions (6.1)</a>]</span>.</p>
<p>The data described in this section are derived from a clinical trial database consisting of 9803 adult and pediatric patients exposed to one or more doses of RISPERDAL<span class="Sup">®</span> for the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span>, and other psychiatric disorders in pediatrics and elderly patients with <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">dementia</span>. Of these 9803 patients, 2687 were patients who received RISPERDAL<span class="Sup">®</span> while participating in double-blind, placebo-controlled trials. The conditions and duration of treatment with RISPERDAL<span class="Sup">®</span> varied greatly and included (in overlapping categories) double-blind, fixed- and flexible-dose, placebo- or active-controlled studies and open-label phases of studies, inpatients and outpatients, and short-term (up to 12 weeks) and longer-term (up to 3 years) exposures. Safety was assessed by collecting adverse events and performing physical examinations, vital signs, body weights, laboratory analyses, and ECGs.</p>
<p>
 
</p>
<p></p>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials – <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Adult Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></p>
<p>Table 8 lists the adverse reactions reported in 2% or more of RISPERDAL<span class="Sup">®</span>-treated adult patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> in three 4- to 8-week, double-blind, placebo-controlled trials.</p>
<table width="100%">
<caption><span>Table 8.        Adverse Reactions in ≥2% of RISPERDAL<span class="Sup">®</span>-Treated Adult Patients (and greater than placebo) with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> in Double-Blind, Placebo-Controlled Trials</span></caption>
<col align="left" span="1" valign="top" width="40%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="center" colspan="3">Percentage of  Patients Reporting Reaction</th>
</tr>
<tr>
<th align="left" colspan="1"></th>
<th align="center" colspan="2">RISPERDAL<span class="Sup">®</span>
</th>
<th align="center" colspan="1"></th>
</tr>
<tr>
<th align="left" colspan="1">System/Organ Class<br>  Adverse Reaction</th>
<th align="center" colspan="1">2–8 mg per day<br>(N=366)</th>
<th align="center" colspan="1">&gt;8–16 mg per  day<br>(N=198)</th>
<th align="center" colspan="1">Placebo<br>(N=225)</th>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span></td>
<td align="center">3</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">9</td>
<td align="center">4</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">8</td>
<td align="center">9</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center">8</td>
<td align="center">6</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td align="center">4</td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal discomfort</span></td>
<td align="center">3</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Salivary hypersecretion</span></td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="Bold">General Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">3</td>
<td align="center">1</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold">Investigations</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4294804" conceptname="Creatine kinase">Blood creatine phosphokinase</span> increased</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">Heart rate increased</span></td>
<td align="center">&lt;1</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td align="center">4</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span></td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span><a href="#footnote-1">*</a>
</td>
<td align="center">14</td>
<td align="center">17</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span><a href="#footnote-1" class="Sup">1</a>
</td>
<td align="center">10</td>
<td align="center">10</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  Sedation</td>
<td align="center">10</td>
<td align="center">5</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">7</td>
<td align="center">4</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span><a href="#footnote-1" class="Sup">1</a>
</td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span><a href="#footnote-1" class="Sup">1</a>
</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4250121" conceptname="Dizziness on standing up">Dizziness postural</span></td>
<td align="center">2</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold">Psychiatric Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center">32</td>
<td align="center">25</td>
<td align="center">27</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td align="center">16</td>
<td align="center">11</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left"><span class="Bold">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span></td>
<td align="center">4</td>
<td align="center">6</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td align="center">&lt;1</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center">1</td>
<td align="center">4</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span></td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">0</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a></p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Pediatric Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></p>
<p>Table 9 lists the adverse reactions reported in 5% or more of RISPERDAL<span class="Sup">®</span>-treated pediatric patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> in a 6-week double-blind, placebo-controlled trial.</p>
<table width="100%">
<caption><span>Table 9. Adverse Reactions in ≥5% of RISPERDAL<span class="Sup">®</span>-Treated Pediatric Patients (and greater than placebo) with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> in a Double-Blind Trial</span></caption>
<col align="left" span="1" valign="top" width="40%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="center" colspan="3">Percentage of  Patients Reporting Reaction</th>
</tr>
<tr>
<th align="left" colspan="1"></th>
<th align="center" colspan="2">RISPERDAL<span class="Sup">®</span>
</th>
<th align="center" colspan="1"></th>
</tr>
<tr>
<th align="left" colspan="1">System/Organ Class<br>  Adverse Reaction</th>
<th align="center" colspan="1">1–3 mg per day<br>(N=55)</th>
<th align="center" colspan="1">4–6 mg per day<br>(N=51)</th>
<th align="center" colspan="1">Placebo<br>(N=54)</th>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Salivary hypersecretion</span></td>
<td align="center">0</td>
<td align="center">10</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  Sedation</td>
<td align="center">24</td>
<td align="center">12</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span><a href="#footnote-1">*</a>
</td>
<td align="center">16</td>
<td align="center">28</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td align="center">11</td>
<td align="center">10</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span><a href="#footnote-2" class="Sup">2</a>
</td>
<td align="center">9</td>
<td align="center">10</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">7</td>
<td align="center">14</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span><a href="#footnote-2" class="Sup">2</a>
</td>
<td align="center">2</td>
<td align="center">6</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold">Psychiatric Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td align="center">7</td>
<td align="center">6</td>
<td align="center">0</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-2" href="#footnote-2" class="Sup">2</a></p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials – Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Adult Patients with Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></span></p>
<p>Table 10 lists the adverse reactions reported in 1% or more of RISPERDAL<span class="Sup">®</span>-treated adult patients with bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> in four 3-week, double-blind, placebo-controlled monotherapy trials.</p>
<table width="100%">
<caption><span>Table 10. Adverse Reactions in ≥2% of RISPERDAL<span class="Sup">®</span>-Treated Adult Patients (and greater than placebo) with Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> in Double-Blind, Placebo-Controlled Monotherapy Trials</span></caption>
<col align="left" span="1" valign="top" width="50%">
<col align="center" span="1" valign="top" width="25%">
<col align="center" span="1" valign="top" width="25%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="center" colspan="2">Percentage of Patients Reporting Reaction</th>
</tr>
<tr>
<th align="left" colspan="1">System/Organ Class<br>  Adverse Reaction</th>
<th align="center" colspan="1">RISPERDAL<span class="Sup">®</span><br>1–6 mg per day<br>(N=448)</th>
<th align="center" colspan="1">Placebo<br>(N=424)</th>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span></td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">5</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Salivary hypersecretion</span></td>
<td align="center">3</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">Stomach discomfort</span></td>
<td align="center">2</td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td align="left"><span class="Bold">General Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span><a href="#footnote-1">*</a>
</td>
<td align="center">25</td>
<td align="center">9</td>
</tr>
<tr>
<td align="left">  Sedation</td>
<td align="center">11</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span><a href="#footnote-3" class="Sup">3</a>
</td>
<td align="center">9</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span><a href="#footnote-3" class="Sup">3</a>
</td>
<td align="center">6</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">6</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span><a href="#footnote-3" class="Sup">3</a>
</td>
<td align="center">5</td>
<td align="center">1</td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-3" href="#footnote-3" class="Sup">3</a></p>
<p>Table 11 lists the adverse reactions reported in 2% or more of RISPERDAL<span class="Sup">®</span>-treated adult patients with bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> in two 3-week, double-blind, placebo-controlled adjuvant therapy trials.</p>
<table width="100%">
<caption><span>Table 11. Adverse Reactions in  ≥2% of RISPERDAL®-Treated Adult Patients (and greater than placebo) with Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> in Double-Blind, Placebo-Controlled Adjunctive Therapy Trials</span></caption>
<col align="left" span="1" valign="top" width="40%">
<col align="center" span="1" valign="top" width="35%">
<col align="center" span="1" valign="top" width="25%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="center" colspan="2">Percentage of Patients Reporting Reaction</th>
</tr>
<tr>
<th align="left" colspan="1">
<br>System/Organ Class</th>
<th align="center" colspan="1">RISPERDAL<span class="Sup">®</span> + Mood Stabilizer</th>
<th align="center" colspan="1">Placebo +<br>Mood Stabilizer</th>
</tr>
<tr>
<th align="left" colspan="1">  Adverse Reaction</th>
<th align="center" colspan="1">(N=127)</th>
<th align="center" colspan="1">(N=126)</th>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center">9</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">6</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">6</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Salivary hypersecretion</span></td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold">General Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span><a href="#footnote-2">*</a>
</td>
<td align="center">14</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  Sedation</td>
<td align="center">9</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span><a href="#footnote-4" class="Sup">4</a>
</td>
<td align="center">8</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">7</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td align="center">6</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left"><span class="Bold">Psychiatric Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="Bold">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td align="center">5</td>
<td align="center">2</td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-4" href="#footnote-4" class="Sup">4</a></p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Pediatric Patients with Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span></span></p>
<p>Table 12 lists the adverse reactions reported in 5% or more of RISPERDAL<span class="Sup">®</span>-treated pediatric patients with bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> in a 3-week double-blind, placebo-controlled trial.</p>
<table width="100%">
<caption><span>Table 12.   Adverse Reactions in ≥5% of RISPERDAL<span class="Sup">®</span>-Treated Pediatric Patients (and greater than placebo) with Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> in Double-Blind, Placebo-Controlled Trials</span></caption>
<col align="left" span="1" valign="top" width="40%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="center" colspan="3">Percentage of  Patients Reporting Reaction</th>
</tr>
<tr>
<th align="left" colspan="1"></th>
<th align="center" colspan="2">RISPERDAL <span class="Sup">®</span>
</th>
<th align="center" colspan="1"></th>
</tr>
<tr>
<th align="left" colspan="1">System/Organ Class<br>  Adverse Reaction</th>
<th align="center" colspan="1">0.5–2.5 mg per  day<br>(N=50)	</th>
<th align="center" colspan="1">3–6 mg per day<br>(N=61)</th>
<th align="center" colspan="1">Placebo<br>(N=58)</th>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span></td>
<td align="center">4</td>
<td align="center">7</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></td>
<td align="center">16</td>
<td align="center">13</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">16</td>
<td align="center">13</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">10</td>
<td align="center">10</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">8</td>
<td align="center">7</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center">10</td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4152197" conceptname="Stomach ache">Stomach discomfort</span></td>
<td align="center">6</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="Bold">General Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">18</td>
<td align="center">30</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left"><span class="Bold">Metabolism and Nutrition Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span></td>
<td align="center">4</td>
<td align="center">7</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  Sedation</td>
<td align="center">42</td>
<td align="center">56</td>
<td align="center">19</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">16</td>
<td align="center">13</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span><a href="#footnote-1">*</a>
</td>
<td align="center">6</td>
<td align="center">12</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span><a href="#footnote-5" class="Sup">5</a>
</td>
<td align="center">6</td>
<td align="center">5</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span><a href="#footnote-5" class="Sup">5</a>
</td>
<td align="center">0</td>
<td align="center">8</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left"><span class="Bold">Psychiatric Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td align="center">0</td>
<td align="center">8</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left"><span class="Bold">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td align="center">10</td>
<td align="center">3</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center">0</td>
<td align="center">7</td>
<td align="center">2</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-5" href="#footnote-5" class="Sup">5</a></p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Commonly-Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials - <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">Autistic Disorder</span></span></p>
<p>Table 13 lists the adverse reactions reported in 5% or more of RISPERDAL<span class="Sup">®</span>-treated pediatric patients treated for <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> associated with <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span> in two 8-week, double-blind, placebo-controlled trials and one 6-week double-blind, placebo-controlled study.</p>
<table width="100%">
<caption><span>Table 13. Adverse Reactions in ≥5% of RISPERDAL<span class="Sup">®</span>-Treated Pediatric Patients (and greater than placebo) Treated for <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span> Associated with <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">Autistic Disorder</span> in Double-Blind, Placebo-Controlled Trials</span></caption>
<col align="left" span="1" valign="top" width="55%">
<col align="left" span="1" valign="top" width="25%">
<col align="left" span="1" valign="top" width="20%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="left" colspan="2">Percentage of Patients Reporting Reaction</th>
</tr>
<tr>
<th align="left" colspan="1">System/Organ Class</th>
<th align="left" colspan="1">RISPERDAL<span class="Sup">®</span><br>0.5–4.0 mg/day</th>
<th align="left" colspan="1">Placebo</th>
</tr>
<tr>
<th align="left" colspan="1">  Adverse Reaction</th>
<th align="left" colspan="1">(N=107)</th>
<th align="left" colspan="1">(N=115)</th>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="left">20</td>
<td align="left">17</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="left">17</td>
<td align="left">6</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td align="left">10</td>
<td align="left">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="left">8</td>
<td align="left">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Salivary hypersecretion</span></td>
<td align="left">7</td>
<td align="left">1</td>
</tr>
<tr>
<td align="left">
<span class="Bold">General Disorders and Administration Site</span> Conditions</td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="left">31</td>
<td align="left">9</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td align="left">16</td>
<td align="left">13</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">Thirst</span></td>
<td align="left">7</td>
<td align="left">4</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4197268" conceptname="Nasopharyngitis">Nasopharyngitis</span></td>
<td align="left">19</td>
<td align="left">9</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td align="left">9</td>
<td align="left">7</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td align="left">8</td>
<td align="left">3</td>
</tr>
<tr>
<td align="left"><span class="Bold">Investigations</span></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increased</span></td>
<td align="left">8</td>
<td align="left">2</td>
</tr>
<tr>
<td align="left"><span class="Bold">Metabolism and Nutrition Disorders</span></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4217027" conceptname="Increased appetite">Increased appetite</span></td>
<td align="left">44</td>
<td align="left">15</td>
</tr>
<tr>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  Sedation</td>
<td align="left">63</td>
<td align="left">15</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4266842" conceptname="Dribbling from mouth">Drooling</span></td>
<td align="left">12</td>
<td align="left">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="left">12</td>
<td align="left">10</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td align="left"><span class="Bold">8</span></td>
<td align="left"><span class="Bold">1</span></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="left">8</td>
<td align="left">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span><a href="#footnote-1">*</a>
</td>
<td align="left">8</td>
<td align="left">1</td>
</tr>
<tr>
<td align="left"><span class="Bold">Renal and Urinary Disorders</span></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">Enuresis</span></td>
<td align="left">16</td>
<td align="left">10</td>
</tr>
<tr>
<td align="left"><span class="Bold">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td align="left">17</td>
<td align="left">12</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">Rhinorrhea</span></td>
<td align="left">12</td>
<td align="left">10</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span></td>
<td align="left">10</td>
<td align="left">4</td>
</tr>
<tr>
<td align="left"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="left">8</td>
<td align="left">5</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-6" href="#footnote-6" class="Sup">6</a></p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Other Adverse Reactions Observed During the Clinical Trial Evaluation of Risperidone</span></p>
<p>The following additional adverse reactions occurred across all placebo-controlled, active-controlled, and open-label studies of RISPERDAL in adults and pediatric patients.</p>
<p>Blood and Lymphatic System Disorders: <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span></p>
<p><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>: <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>, <span class="product-label-link" type="condition" conceptid="314379" conceptname="First degree atrioventricular block">atrioventricular block first degree</span>, <span class="product-label-link" type="condition" conceptid="313209" conceptname="Left bundle branch hemiblock">bundle branch block left</span>, <span class="product-label-link" type="condition" conceptid="314059" conceptname="Right bundle branch block">bundle branch block right</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span></p>
<p>Ear and Labyrinth Disorders: <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">ear pain</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></p>
<p><span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">Endocrine Disorders</span>: <span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">hyperprolactinemia</span></p>
<p><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>: <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">ocular hyperemia</span>, <span class="product-label-link" type="condition" conceptid="4080696" conceptname="Discharge from eye">eye discharge</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4012867" conceptname="Rolling of eyes">eye rolling</span>, <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">eyelid edema</span>, <span class="product-label-link" type="condition" conceptid="381299" conceptname="Swelling of structure of eye">eye swelling</span>, eyelid margin crusting, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation increased</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, <span class="product-label-link" type="condition" conceptid="376402" conceptname="Low vision, one eye">visual acuity reduced</span></p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4258683" conceptname="Fecal impaction">fecaloma</span>, <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">fecal incontinence</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="44783305" conceptname="Lip swelling">lip swelling</span>, <span class="product-label-link" type="condition" conceptid="4301764" conceptname="Cheilitis">cheilitis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">aptyalism</span></p>
<p>General Disorders: <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">gait disturbance</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>-like illness, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">pitting edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">sluggishness</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="441260" conceptname="Drug withdrawal">drug withdrawal syndrome</span>, <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">peripheral coldness</span>, <span class="product-label-link" type="condition" conceptid="4075224" conceptname="Feeling bad">feeling abnormal</span></p>
<p><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span>: <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span></p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>: <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span>, <span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">ear infection</span>, <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4134613" conceptname="Eye infection">eye infection</span>, <span class="product-label-link" type="condition" conceptid="4018050" conceptname="Localized infection">localized infection</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="4215978" conceptname="Onychomycosis">onychomycosis</span>, <span class="product-label-link" type="condition" conceptid="140949" conceptname="Infestation by Sarcoptes scabiei var hominis">acarodermatitis</span>, <span class="product-label-link" type="condition" conceptid="256722" conceptname="Bronchopneumonia">bronchopneumonia</span>, <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="4028970" conceptname="Tracheobronchitis">tracheobronchitis</span>, <span class="product-label-link" type="condition" conceptid="260730" conceptname="Chronic atticoantral suppurative otitis media">otitis media chronic</span></p>
<p>Investigations: body temperature increased, <span class="product-label-link" type="condition" conceptid="4035688" conceptname="Increased prolactin level">blood prolactin increased</span>, <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> increased, <span class="product-label-link" type="condition" conceptid="320536" conceptname="Electrocardiogram abnormal">electrocardiogram abnormal</span>, eosinophil count increased, white blood cell count decreased, blood glucose increased, <span class="product-label-link" type="condition" conceptid="4013074" conceptname="Hemoglobin low">hemoglobin decreased</span>, <span class="product-label-link" type="condition" conceptid="4216894" conceptname="Precipitous drop in hematocrit">hematocrit decreased</span>, body temperature decreased, <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">blood pressure decreased</span>, transaminases increased</p>
<p>Metabolism and Nutrition Disorders: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="432454" conceptname="Excessive thirst">polydipsia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span></p>
<p>Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">Connective Tissue Disorders</span>: <span class="product-label-link" type="condition" conceptid="72404" conceptname="Joint stiffness">joint stiffness</span>, <span class="product-label-link" type="condition" conceptid="4154927" conceptname="Joint swelling">joint swelling</span>, <span class="product-label-link" type="condition" conceptid="4092930" conceptname="Musculoskeletal chest pain">musculoskeletal chest pain</span>, <span class="product-label-link" type="condition" conceptid="439935" conceptname="Abnormal posture">posture abnormal</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="24134" conceptname="Neck pain">neck pain</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span></p>
<p><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>: <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">balance disorder</span>, <span class="product-label-link" type="condition" conceptid="4096147" conceptname="Poor concentration">disturbance in attention</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4309389" conceptname="Unresponsive">unresponsive to stimuli</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">depressed level of consciousness</span>, <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">movement disorder</span>, transient ischemic attack, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">coordination abnormal</span>, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, speech disorder, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoesthesia</span>, <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, <span class="product-label-link" type="condition" conceptid="434056" conceptname="Late effects of cerebrovascular disease">cerebrovascular disorder</span>, <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>, <span class="product-label-link" type="condition" conceptid="4095288" conceptname="Diabetic coma with ketoacidosis">diabetic coma</span>, head titubation</p>
<p>Psychiatric Disorders: <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4264021" conceptname="Blunted affect">blunted affect</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusional state</span>, <span class="product-label-link" type="condition" conceptid="4282607" conceptname="Middle insomnia">middle insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">sleep disorder</span>, <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">listlessness</span>, <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">libido decreased</span>, and <span class="product-label-link" type="condition" conceptid="4269918" conceptname="Orgasm incapacity">anorgasmia</span></p>
<p>Renal and Urinary Disorders: <span class="product-label-link" type="condition" conceptid="193874" conceptname="Nocturnal enuresis">enuresis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">pollakiuria</span>, <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span></p>
<p>Reproductive System and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">Breast Disorders</span>: <span class="product-label-link" type="condition" conceptid="196168" conceptname="Irregular periods">menstruation irregular</span>, <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">amenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span>, <span class="product-label-link" type="condition" conceptid="4155070" conceptname="Vaginal discharge">vaginal discharge</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">menstrual disorder</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, <span class="product-label-link" type="condition" conceptid="435866" conceptname="Retrograde ejaculation">retrograde ejaculation</span>, <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorder</span>, <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual dysfunction</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span></p>
<p>Respiratory, Thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>: <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="252663" conceptname="Pneumonitis due to inhalation of food or vomitus">pneumonia aspiration</span>, <span class="product-label-link" type="condition" conceptid="4220211" conceptname="Congestion of nasal sinus">sinus congestion</span>, <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">productive cough</span>, <span class="product-label-link" type="condition" conceptid="4194173" conceptname="Pulmonary congestion">pulmonary congestion</span>, <span class="product-label-link" type="condition" conceptid="4170108" conceptname="Respiratory tract congestion">respiratory tract congestion</span>, <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">rales</span>, <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorder</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, nasal <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></p>
<p>Skin and Subcutaneous Tissue Disorders: <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>, <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">skin lesion</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">skin disorder</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> erythematous, <span class="product-label-link" type="condition" conceptid="141094" conceptname="Lichen">rash papular</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> generalized, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> maculopapular, <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>, <span class="product-label-link" type="condition" conceptid="4098436" conceptname="Hyperkeratosis">hyperkeratosis</span>, <span class="product-label-link" type="condition" conceptid="137053" conceptname="Seborrheic dermatitis">seborrheic dermatitis</span></p>
<p><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>: <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Additional Adverse Reactions Reported with RISPERDAL<span class="Sup">®</span> CONSTA<span class="Sup">®</span></span></p>
<p>The following is a list of additional adverse reactions that have been reported during the premarketing evaluation of RISPERDAL<span class="Sup">®</span> CONSTA<span class="Sup">®</span>, regardless of frequency of occurrence:</p>
<p><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>: <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span></p>
<p>Ear and Labyrinth Disorders: <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span></p>
<p><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span>: <span class="product-label-link" type="condition" conceptid="435802" conceptname="Blepharospasm">blepharospasm</span></p>
<p><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">toothache</span>, tongue spasm</p>
<p>General Disorders and Administration Site Conditions: <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
<p><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>: <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="4339469" conceptname="Abscess of external ear">subcutaneous abscess</span></p>
<p>Injury and <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span>: <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span></p>
<p>Investigations: <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decreased</span>, gamma-glutamyltransferase increased, hepatic enzyme increased</p>
<p>Musculoskeletal, Connective Tissue, and <span class="product-label-link" type="condition" conceptid="75909" conceptname="Disorder of bone">Bone Disorders</span>: <span class="product-label-link" type="condition" conceptid="4133039" conceptname="Pain in buttock">buttock pain</span></p>
<p><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>: <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span></p>
<p>Psychiatric Disorders: <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></p>
<p>Skin and Subcutaneous Tissue Disorders: <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">eczema</span></p>
<p><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular Disorders</span>: <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span></p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Discontinuations Due to Adverse Reactions</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> - Adults</span></p>
<p>Approximately 7% (39/564) of RISPERDAL<span class="Sup">®</span>-treated patients in double-blind, placebo-controlled trials discontinued treatment due to an adverse reaction, compared with 4% (10/225) who were receiving placebo. The adverse reactions associated with discontinuation in 2 or more RISPERDAL<span class="Sup">®</span>-treated patients were:</p>
<table width="100%">
<caption><span>Table 14.  Adverse Reactions Associated With Discontinuation in 2 or More RISPERDAL<span class="Sup">®</span>-Treated Adult Patients in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> Trials</span></caption>
<col align="left" span="1" valign="top" width="25%">
<col align="center" span="1" valign="top" width="25%">
<col align="center" span="1" valign="top" width="25%">
<col align="center" span="1" valign="top" width="25%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"></th>
<th align="center" colspan="2">RISPERDAL<span class="Sup">®</span>
</th>
<th align="center" colspan="1"></th>
</tr>
<tr>
<th align="left" colspan="1">Adverse Reaction</th>
<th align="center" colspan="1">2–8 mg/day<br>(N=366)</th>
<th align="center" colspan="1">&gt;8–16 mg/day<br>(N=198)</th>
<th align="center" colspan="1">Placebo<br>(N=225)</th>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">1.4%</td>
<td align="center">1.0%</td>
<td align="center">0%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">1.4%</td>
<td align="center">0%</td>
<td align="center">0%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">0.8%</td>
<td align="center">0%</td>
<td align="center">0%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span></td>
<td align="center">0.8%</td>
<td align="center">0%</td>
<td align="center">0%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">0.8%</td>
<td align="center">0%</td>
<td align="center">0%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span></td>
<td align="center">0.5%</td>
<td align="center">0%</td>
<td align="center">0%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></td>
<td align="center">0.5%</td>
<td align="center">0%</td>
<td align="center">0%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="center">0.5%</td>
<td align="center">0%</td>
<td align="center">0%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span></td>
<td align="center">0.3%</td>
<td align="center">0.5%</td>
<td align="center">0%</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span></td>
<td align="center">0.3%</td>
<td align="center">2.0%</td>
<td align="center">0%</td>
</tr>
</tbody>
</table>
<p>Discontinuation for <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> (including <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, and <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>) was 1% in placebo-treated patients, and 3.4% in active control-treated patients in a double-blind, placebo- and active-controlled trial.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span> - Pediatrics</span></p>
<p>Approximately 7% (7/106), of RISPERDAL<span class="Sup">®</span>-treated patients discontinued treatment due to an adverse reaction in a double-blind, placebo-controlled trial, compared with 4% (2/54) placebo-treated patients. The adverse reactions associated with discontinuation for at least one RISPERDAL<span class="Sup">®</span>-treated patient were <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (2%), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (1%), sedation (1%), <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> (1%), <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span> (1%), <span class="product-label-link" type="condition" conceptid="4046907" conceptname="Dysequilibrium syndrome">balance disorder</span> (1%), <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (1%), and <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span> (1%).</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> - Adults</span></p>
<p>In double-blind, placebo-controlled trials with RISPERDAL<span class="Sup">®</span> as monotherapy, approximately 6% (25/448) of RISPERDAL<span class="Sup">®</span>-treated patients discontinued treatment due to an adverse event, compared with approximately 5% (19/424) of placebo-treated patients. The adverse reactions associated with discontinuation in RISPERDAL<span class="Sup">®</span>-treated patients were:</p>
<table width="75%">
<caption><span>Table 15.  Adverse Reactions Associated With Discontinuation in 2 or More RISPERDAL<span class="Sup">®</span>-Treated Adult Patients in Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> Clinical Trials</span></caption>
<col align="left" span="1" valign="top" width="50%">
<col align="center" span="1" valign="top" width="25%">
<col align="center" span="1" valign="top" width="25%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Adverse Reaction</th>
<th align="center" colspan="1">RISPERDAL<span class="Sup">®</span><br>1–6 mg/day<br>(N=448)</th>
<th align="center" colspan="1">Placebo<br>(N=424)</th>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span></td>
<td align="center">0.4%</td>
<td align="center">0%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td align="center">0.2%</td>
<td align="center">0%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">0.2%</td>
<td align="center">0%</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span> increased</td>
<td align="center">0.2%</td>
<td align="center">0.2%</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span> increased</td>
<td align="center">0.2%</td>
<td align="center">0.2%</td>
</tr>
</tbody>
</table>
<p>
 
</p>
<p></p>
<p><span class="Italics">Bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> - Pediatrics</span></p>
<p>In a double-blind, placebo-controlled trial 12% (13/111) of RISPERDAL<span class="Sup">®</span>-treated patients discontinued due to an adverse reaction, compared with 7% (4/58) of placebo-treated patients. The adverse reactions associated with discontinuation in more than one RISPERDAL<span class="Sup">®</span>-treated pediatric patient were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (3%), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (2%), sedation (2%), and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (2%).</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">Autistic Disorder</span> - Pediatrics</span></p>
<p>In the two 8-week, placebo-controlled trials in pediatric patients treated for <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> associated with <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span> (n = 156), one RISPERDAL<span class="Sup">®</span>-treated patient discontinued due to an adverse reaction (<span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span>), and one placebo-treated patient discontinued due to an adverse event.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Dose Dependency of Adverse Reactions in Clinical Trials</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">Extrapyramidal Symptoms</span></span></p>
<p>Data from two fixed-dose trials in adults with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> provided evidence of dose-relatedness for <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> associated with RISPERDAL<span class="Sup">®</span> treatment.</p>
<p>Two methods were used to measure <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> (EPS) in an 8-week trial comparing 4 fixed doses of RISPERDAL<span class="Sup">®</span> (2, 6, 10, and 16 mg/day), including (1) a <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> score (mean change from baseline) from the Extrapyramidal Symptom Rating Scale, and (2) incidence of spontaneous complaints of EPS:</p>
<table width="100%">
<caption><span>Table 16.</span></caption>
<col align="left" span="1" valign="top" width="17%">
<col align="center" span="1" valign="top" width="17%">
<col align="center" span="1" valign="top" width="17%">
<col align="center" span="1" valign="top" width="17%">
<col align="center" span="1" valign="top" width="16%">
<col align="center" span="1" valign="top" width="16%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Dose Groups</th>
<th align="center" colspan="1">Placebo</th>
<th align="center" colspan="1">RISPERDAL<span class="Sup">®</span> 2 mg</th>
<th align="center" colspan="1">RISPERDAL<span class="Sup">®</span> 6 mg</th>
<th align="center" colspan="1">RISPERDAL<span class="Sup">®</span> 10 mg</th>
<th align="center" colspan="1">RISPERDAL<span class="Sup">®</span> 16 mg</th>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span></td>
<td align="center">1.2</td>
<td align="center">0.9</td>
<td align="center">1.8</td>
<td align="center">2.4</td>
<td align="center">2.6</td>
</tr>
<tr class="Last">
<td align="left">EPS Incidence</td>
<td align="center">13%</td>
<td align="center">17%</td>
<td align="center">21%</td>
<td align="center">21%</td>
<td align="center">35%</td>
</tr>
</tbody>
</table>
<p>Similar methods were used to measure <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span> (EPS) in an 8-week trial comparing 5 fixed doses of RISPERDAL<span class="Sup">®</span> (1, 4, 8, 12, and 16 mg/day):</p>
<table width="100%">
<caption><span>Table 17.</span></caption>
<col align="left" span="1" valign="top" width="17%">
<col align="center" span="1" valign="top" width="17%">
<col align="center" span="1" valign="top" width="17%">
<col align="center" span="1" valign="top" width="17%">
<col align="center" span="1" valign="top" width="16%">
<col align="center" span="1" valign="top" width="16%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Dose Groups</th>
<th align="center" colspan="1">RISPERDAL<span class="Sup">®</span> 1 mg</th>
<th align="center" colspan="1">RISPERDAL<span class="Sup">®</span> 4 mg</th>
<th align="center" colspan="1">RISPERDAL<span class="Sup">®</span> 8 mg</th>
<th align="center" colspan="1">RISPERDAL<span class="Sup">®</span> 12 mg</th>
<th align="center" colspan="1">RISPERDAL<span class="Sup">®</span> 16 mg</th>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span></td>
<td align="center">0.6</td>
<td align="center">1.7</td>
<td align="center">2.4</td>
<td align="center">2.9</td>
<td align="center">4.1</td>
</tr>
<tr class="Last">
<td align="left">EPS Incidence</td>
<td align="center">7%</td>
<td align="center">12%</td>
<td align="center">17%</td>
<td align="center">18%</td>
<td align="center">20%</td>
</tr>
</tbody>
</table>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span></span></p>
<p><span class="Italics">Class Effect:</span> Symptoms of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, prolonged abnormal contractions of muscle groups, may occur in susceptible individuals during the first few days of treatment. Dystonic symptoms include: spasm of the neck muscles, sometimes progressing to tightness of the throat, swallowing difficulty, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, and/or protrusion of the tongue. While these symptoms can occur at low doses, they occur more frequently and with greater severity with high potency and at higher doses of first generation antipsychotic drugs. An elevated risk of <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">acute dystonia</span> is observed in males and younger age groups.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Other Adverse Reactions</span></p>
<p>Adverse event data elicited by a checklist for side effects from a large study comparing 5 fixed doses of RISPERDAL<span class="Sup">®</span> (1, 4, 8, 12, and 16 mg/day) were explored for dose-relatedness of adverse events. A Cochran-Armitage Test for trend in these data revealed a positive trend (p&lt;0.05) for the following adverse reactions: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">vision abnormal</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increase</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorder</span>, <span class="product-label-link" type="condition" conceptid="4237140" conceptname="Abnormal sexual function">sexual function abnormal</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">skin discoloration</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Changes in Body Weight</span></p>
<p><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> was observed in short-term, controlled trials and longer-term uncontrolled studies in adult and pediatric patients <span class="Italics">[see<a href="#S5.5"> Warnings and Precautions (5.5)</a>,<a href="#S6"> Adverse Reactions (6)</a>, and<a href="#S8.4"> Use in Specific Populations (8.4)</a>].</span></p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Changes in ECG Parameters</span></p>
<p>Between-group comparisons for pooled placebo-controlled trials in adults revealed no statistically significant differences between risperidone and placebo in mean changes from baseline in ECG parameters, including QT, QTc, and PR intervals, and heart rate. When all RISPERDAL<span class="Sup">®</span> doses were pooled from randomized controlled trials in several indications, there was a mean increase in heart rate of 1 beat per minute compared to no change for placebo patients. In short-term <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials, higher doses of risperidone (8–16 mg/day) were associated with a higher mean increase in heart rate compared to placebo (4–6 beats per minute). In pooled placebo-controlled <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">acute mania</span> trials in adults, there were small decreases in mean heart rate, similar among all treatment groups.</p>
<p>In the two placebo-controlled trials in children and adolescents with <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span> (aged 5 – 16 years) mean changes in heart rate were an increase of 8.4 beats per minute in the RISPERDAL<span class="Sup">®</span> groups and 6.5 beats per minute in the placebo group. There were no other notable ECG changes.</p>
<p>In a placebo-controlled <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">acute mania</span> trial in children and adolescents (aged 10 – 17 years), there were no significant changes in ECG parameters, other than the effect of RISPERDAL<span class="Sup">®</span> to transiently increase pulse rate (&lt; 6 beats per minute). In two controlled <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials in adolescents (aged 13 – 17 years), there were no clinically meaningful changes in ECG parameters including corrected QT intervals between treatment groups or within treatment groups over time.</p>
<p>
 
</p>
<p></p>
<p>The following adverse reactions have been identified during postapproval use of risperidone. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These adverse reactions include: <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4256374" conceptname="Cardiorespiratory arrest">cardiopulmonary arrest</span>, <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> in patients with impaired glucose metabolism, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate antidiuretic hormone secretion</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenoma</span>, <span class="product-label-link" type="condition" conceptid="4267558" conceptname="Precocious puberty">precocious puberty</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, QT prolongation, <span class="product-label-link" type="condition" conceptid="313459" conceptname="Sleep apnea">sleep apnea syndrome</span>, <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4301602" conceptname="Thrombotic thrombocytopenic purpura">thrombotic thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, and <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span>.</p>
<p>
 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> includes <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">musculoskeletal stiffness</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="4208094" conceptname="Cogwheel muscle rigidity">cogwheel rigidity</span>, <span class="product-label-link" type="condition" conceptid="4143471" conceptname="Akinesia">akinesia</span>, <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">bradykinesia</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="4013001" conceptname="Masklike facies">masked facies</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, and Parkinson's disease. <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> includes <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> and <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>. <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span> includes <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">muscle contractions involuntary</span>, <span class="product-label-link" type="condition" conceptid="4208264" conceptname="Muscle contracture">muscle contracture</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyration</span>, <span class="product-label-link" type="condition" conceptid="4243934" conceptname="Paralysis of tongue">tongue paralysis</span>. <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> includes <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> and <span class="product-label-link" type="condition" conceptid="4008894" conceptname="Pill rolling">parkinsonian rest tremor</span>.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">2</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> includes <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">musculoskeletal stiffness</span>, and <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>. <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> includes <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> and <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>. <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span> includes <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span> and <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyration</span>.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">3</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> includes <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span>, <span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">parkinsonism</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">musculoskeletal stiffness</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="4097447" conceptname="Muscle tension">muscle tightness</span>, <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">bradykinesia</span>, <span class="product-label-link" type="condition" conceptid="4208094" conceptname="Cogwheel muscle rigidity">cogwheel rigidity</span>. <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> includes <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span> and <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>. <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span> includes <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span> and <span class="product-label-link" type="condition" conceptid="4008894" conceptname="Pill rolling">parkinsonian rest tremor</span>. <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span> includes <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>, <span class="product-label-link" type="condition" conceptid="4205592" conceptname="Oculogyric crisis">oculogyration</span>, <span class="product-label-link" type="condition" conceptid="440814" conceptname="Torticollis">torticollis</span>.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">4</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> includes <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span>, <span class="product-label-link" type="condition" conceptid="4195475" conceptname="Behavior showing reduced motor activity">hypokinesia</span> and <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">bradykinesia</span>. <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> includes <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">hyperkinesia</span> and <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">5</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> includes <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">musculoskeletal stiffness</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span>, <span class="product-label-link" type="condition" conceptid="4161417" conceptname="Bradykinesia">bradykinesia</span>, and <span class="product-label-link" type="condition" conceptid="4228784" conceptname="Nuchal rigidity">nuchal rigidity</span>. <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">Dystonia</span> includes <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span>, and <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasms</span>. <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">Akathisia</span> includes <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span> and <span class="product-label-link" type="condition" conceptid="4108925" conceptname="Akathisia">akathisia</span>.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">6</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="4140090" conceptname="Parkinsonism">Parkinsonism</span> includes <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">musculoskeletal stiffness</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal disorder</span>, <span class="product-label-link" type="condition" conceptid="4050941" conceptname="Muscle rigidity">muscle rigidity</span>, <span class="product-label-link" type="condition" conceptid="4208094" conceptname="Cogwheel muscle rigidity">cogwheel rigidity</span>, and <span class="product-label-link" type="condition" conceptid="4097447" conceptname="Muscle tension">muscle tightness</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<p class="First"></p>
<ul>
<li>Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone. Increase the RISPERDAL<span class="Sup">®</span> dose up to double the patient's usual dose. Titrate slowly. (<a href="#S7.1">7.1</a>)</li>
<li>Fluoxetine, paroxetine, and other CYP 2D6 enzyme inhibitors increase plasma concentrations of risperidone. Reduce the initial dose. Do not exceed a final dose of 8 mg per day of RISPERDAL<span class="Sup">®</span>. (<a href="#S7.1">7.1</a>)</li>
</ul>
<p>
 
</p>
<p></p>
<p>The dose of RISPERDAL<span class="Sup">®</span> should be adjusted when used in combination with CYP2D6 enzyme inhibitors (e.g., fluoxetine, and paroxetine) and enzyme inducers (e.g., carbamazepine) <span class="Italics">[see<a href="#table18"> Table 18 </a>and<a href="#S2.5"> Dosage and Administration (2.5)</a>]</span>. Dose adjustment is not recommended for RISPERDAL<span class="Sup">®</span> when co-administered with ranitidine, cimetidine, amitriptyline, or erythromycin <span class="Italics">[see<a href="#table18"> Table 18</a>].</span></p>
<a name="table18"></a><table width="100%">
<caption><span>Table 18  Summary of Effect of Coadministered Drugs on Exposure to Active Moiety (Risperidone + 9-Hydroxy-Risperidone) in Healthy Subjects or Patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></caption>
<col align="left" span="1" valign="top" width="19%">
<col align="left" span="1" valign="top" width="19%">
<col align="left" span="1" valign="top" width="19%">
<col align="left" span="1" valign="top" width="12%">
<col align="left" span="1" valign="top" width="12%">
<col align="left" span="1" valign="top" width="19%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Coadministered Drug</th>
<th align="left" colspan="2">Dosing Schedule</th>
<th align="left" colspan="2">Effect on Active Moiety (Risperidone  + 9-Hydroxy-Risperidone (Ratio<a href="#footnote-1">*</a>)</th>
<th align="left" colspan="1">Risperidone Dose Recommendation</th>
</tr>
<tr>
<th align="left" colspan="1">Coadministered Drug</th>
<th align="left" colspan="1">Risperidone</th>
<th align="left" colspan="1">AUC</th>
<th align="left" colspan="1">Cmax</th>
</tr>
<tr>
<td align="left">Enzyme (CYP2D6) Inhibitors</td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">Fluoxetine</td>
<td align="left">20 mg/day</td>
<td align="left">2 or 3 mg twice daily</td>
<td align="left">1.4</td>
<td align="left">1.5</td>
<td align="left">Re-evaluate dosing. Do not exceed 8 mg/day</td>
</tr>
<tr>
<td align="left">Paroxetine</td>
<td align="left">10 mg/day</td>
<td align="left">4 mg/day</td>
<td align="left">1.3</td>
<td align="left">-</td>
<td align="left">Re-evaluate dosing. Do not exceed 8 mg/day</td>
</tr>
<tr>
<td align="left"></td>
<td align="left">20 mg/day</td>
<td align="left">4 mg/day</td>
<td align="left">1.6</td>
<td align="left">-</td>
</tr>
<tr>
<td align="left"></td>
<td align="left">40 mg/day</td>
<td align="left">4 mg/day</td>
<td align="left">1.8</td>
<td align="left">-</td>
</tr>
<tr>
<td align="left">Enzyme (CYP3A/ PgP inducers) Inducers</td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">Carbamazepine</td>
<td align="left">573 ± 168 mg/day</td>
<td align="left">3 mg twice daily</td>
<td align="left">0.51</td>
<td align="left">0.55</td>
<td align="left">Titrate dose upwards. Do not exceed twice the patient's usual dose</td>
</tr>
<tr>
<td align="left">Enzyme (CYP3A) Inhibitors</td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">Ranitidine</td>
<td align="left">150 mg twice daily</td>
<td align="left">1 mg single dose</td>
<td align="left">1.2</td>
<td align="left">1.4</td>
<td align="left">Dose adjustment not needed</td>
</tr>
<tr>
<td align="left">Cimetidine</td>
<td align="left">400 mg twice daily</td>
<td align="left">1 mg single dose</td>
<td align="left">1.1</td>
<td align="left">1.3</td>
<td align="left">Dose adjustment not needed</td>
</tr>
<tr>
<td align="left">Erythromycin</td>
<td align="left">500 mg four times daily</td>
<td align="left">1 mg single dose</td>
<td align="left">1.1</td>
<td align="left">0.94</td>
<td align="left">Dose adjustment not needed</td>
</tr>
<tr>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">Other  Drugs</td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr class="Last">
<td align="left">Amitriptyline</td>
<td align="left">50 mg twice daily</td>
<td align="left">3 mg twice daily</td>
<td align="left">1.2</td>
<td align="left">1.1</td>
<td align="left">Dose adjustment not needed</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-7" href="#footnote-7" class="Sup">7</a></p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Effect of Risperidone on other drugs</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Lithium</span></p>
<p>Repeated oral doses of RISPERDAL<span class="Sup">®</span> (3 mg twice daily) did not affect the exposure (AUC) or peak plasma concentrations (C<span class="Sub">max</span>) of lithium (n=13). Dose adjustment for lithium is not recommended.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Valproate</span></p>
<p>Repeated oral doses of  RISPERDAL<span class="Sup">®</span> (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (n=21). However, there was a 20% increase in valproate peak plasma concentration (C<span class="Sub">max</span>) after concomitant administration of  RISPERDAL<span class="Sup">®</span>. Dose adjustment for valproate is not recommended.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Digoxin</span></p>
<p>RISPERDAL<span class="Sup">®</span> (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin. Dose adjustment for digoxin is not recommended.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Centrally-Acting Drugs and Alcohol</span></p>
<p>Given the primary CNS effects of risperidone, caution should be used when RISPERDAL<span class="Sup">®</span> is taken in combination with other centrally-acting drugs and alcohol.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Drugs with Hypotensive Effects</span></p>
<p>Because of its potential for inducing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, RISPERDAL<span class="Sup">®</span> may enhance the hypotensive effects of other therapeutic agents with this potential.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Levodopa and Dopamine Agonists</span></p>
<p>RISPERDAL<span class="Sup">®</span> may antagonize the effects of levodopa and dopamine agonists.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Clozapine</span></p>
<p>Chronic administration of clozapine with RISPERDAL<span class="Sup">®</span> may decrease the clearance of risperidone.</p>
<p>
 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">7</a></dt>
<dd>Change relative to reference</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>USE IN SPECIFIC POPULATIONS</h1>
<p class="First"></p>
<ul>
<li>Pregnancy: Based on animal data, may cause fetal harm. (<a href="#S8.1">8.1</a>)</li>
<li>Nursing Mothers: Discontinue drug or nursing, taking into consideration the importance of drug to the mother. (<a href="#S8.3">8.3</a>)</li>
</ul>
<p>
 
</p>
<p></p>
<p><span class="Underline">Pregnancy Category C</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Risk Summary</span></p>
<p>Adequate and well controlled studies with RISPERDAL have not been conducted in pregnant women. Neonates exposed to antipsychotic drugs (including RISPERDAL<span class="Sup">®</span>) during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There was no increase in the incidence of malformations in embryo-fetal studies in rats and rabbits at 0.4–6 times MHRD. Increased pup mortality was noted at all doses in peri-postnatal studies in rats. RISPERDAL<span class="Sup">®</span> should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Clinical Considerations</span></p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Fetal/Neonatal Adverse Reactions</span></p>
<p>Monitor neonates exhibiting extrapyramidal or withdrawal symptoms. Some neonates recover within hours or days without specific treatment; others may require prolonged hospitalization.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Data</span></p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Human Data</span></p>
<p>There have been reports of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonia</span>, <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, and <span class="product-label-link" type="condition" conceptid="434750" conceptname="Feeding difficulties and mismanagement">feeding disorder</span> in neonates following in utero exposure to antipsychotics in the third trimester. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.</p>
<p>There was one report of a case of agenesis of the corpus callosum in an infant exposed to risperidone <span class="Italics">in utero</span>. The causal relationship to RISPERDAL<span class="Sup">®</span> therapy is unknown.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Animal Data</span></p>
<p>The teratogenic potential of risperidone was studied in three Segment II studies in Sprague-Dawley and Wistar rats (0.63–10 mg/kg or 0.4 to 6 times the maximum recommended human dose [MRHD] on a mg/m<span class="Sup">2</span> body surface area basis) and in one Segment II study in New Zealand rabbits (0.31–5 mg/kg or 0.4 to 6 times the MRHD on a mg/m<span class="Sup">2</span> body surface area basis). There were no teratogenic effects in offspring of rats or rabbits given 0.4 to 6 times the MRHD on a mg/m<span class="Sup">2</span> body surface area basis. In three reproductive studies in rats (two Segment III and a multigenerational study), there was an increase in pup <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> during the first 4 days of lactation at doses of 0.16–5 mg/kg or 0.1 to 3 times the MRHD on a mg/m<span class="Sup">2</span> body surface area basis. It is not known whether these <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were due to a direct effect on the fetuses or pups or to effects on the dams.</p>
<p>There was no no-effect dose for increased rat pup mortality. In one Segment III study, there was an increase in stillborn rat pups at a dose of 2.5 mg/kg or 1.5 times the MRHD on a mg/m<span class="Sup">2 </span>body surface area basis. In a cross-fostering study in Wistar rats, toxic effects on the fetus or pups were observed, as evidenced by a decrease in the number of live pups and an increase in the number of dead pups at birth (Day 0), and a decrease in birth weight in pups of drug-treated dams. In addition, there was an increase in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> by Day 1 among pups of drug-treated dams, regardless of whether or not the pups were cross-fostered. Risperidone also appeared to impair maternal behavior in that pup body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and survival (from Day 1 to 4 of lactation) were reduced in pups born to control but reared by drug-treated dams. These effects were all noted at the one dose of risperidone tested, i.e., 5 mg/kg or 3 times the MRHD on a mg/m<span class="Sup">2</span> body surface area basis.</p>
<p>Placental transfer of risperidone occurs in rat pups.</p>
<p>
 
</p>
<p></p>
<p>The effect of RISPERDAL<span class="Sup">®</span> on labor and delivery in humans is unknown.</p>
<p>
 
</p>
<p></p>
<p>Risperidone and 9-hydroxyrisperidone are present in human breast milk. Because of the potential for serious adverse reactions in nursing infants from risperidone, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Approved Pediatric Indications</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">Schizophrenia</span></span></p>
<p>The efficacy and safety of RISPERDAL<span class="Sup">®</span> in the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> were demonstrated in 417 adolescents, aged 13 – 17 years, in two short-term (6 and 8 weeks, respectively) double-blind controlled trials <span class="Italics">[see </span><span class="Italics"><a href="#S1.1">Indications and Usage (1.1)</a></span>, <span class="Italics"><a href="#S6.1">Adverse Reactions (6.1)</a></span>, <span class="Italics">and </span><span class="Italics"><a href="#S14.1">Clinical Studies (14.1)</a>].</span> Additional safety and efficacy information was also assessed in one long-term (6-month) open-label extension study in 284 of these adolescent patients with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>.</p>
<p>Safety and effectiveness of RISPERDAL<span class="Sup">®</span> in children less than 13 years of age with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> have not been established.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span></span></p>
<p>The efficacy and safety of RISPERDAL<span class="Sup">®</span> in the short-term treatment of acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes associated with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> in 169 children and adolescent patients, aged 10 – 17 years, were demonstrated in one double-blind, placebo-controlled, 3-week trial <span class="Italics">[see </span><span class="Italics"><a href="#S1.2">Indications and Usage (1.2)</a></span>,<span class="Italics"><a href="#S6.1"> Adverse Reactions (6.1)</a></span>, <span class="Italics">and </span><span class="Italics"><a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</p>
<p>Safety and effectiveness of RISPERDAL<span class="Sup">®</span> in children less than 10 years of age with bipolar disorder have not been established.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">Autistic Disorder</span></span></p>
<p>The efficacy and safety of RISPERDAL<span class="Sup">®</span> in the treatment of <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> associated with <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span> were established in two 8-week, double-blind, placebo-controlled trials in 156 children and adolescent patients, aged 5 to 16 years <span class="Italics">[see </span><span class="Italics"><a href="#S1.3">Indications and Usage (1.3)</a></span>,<span class="Italics"><a href="#S6.1"> Adverse Reactions (6.1) </a></span><span class="Italics">and </span><span class="Italics"><a href="#S14.4">Clinical Studies (14.4)</a></span><span class="Italics">]</span>. Additional safety information was also assessed in a long-term study in patients with <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span>, or in short- and long-term studies in more than 1200 pediatric patients with psychiatric disorders other than <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span>, <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, or bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> who were of similar age and weight, and who received similar dosages of RISPERDAL<span class="Sup">®</span> as patients treated for <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> associated with <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span>.</p>
<p>A third study was a 6-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of a lower than recommended dose of risperidone in subjects 5 to 17 years of age with <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span> and associated <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, and related behavioral symptoms. There were two weight-based, fixed doses of risperidone (high-dose and low-dose). The high dose was 1.25 mg per day for patients weighing 20 to &lt; 45 kg, and it was 1.75 mg per day for patients weighing ≥ 45 kg. The low dose was 0.125 mg per day for patients for patients weighing 20 to &lt; 45 kg, and it was 0.175 mg per day for patients weighing ≥ 45 kg. The study demonstrated the efficacy of high-dose risperidone, but it did not demonstrate efficacy for low-dose risperidone.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Adverse Reactions in Pediatric Patients</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">Tardive Dyskinesia</span></span></p>
<p>In clinical trials in 1885 children and adolescents treated with RISPERDAL<span class="Sup">®</span>, 2 (0.1%) patients were reported to have <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span>, which resolved on discontinuation of RISPERDAL<span class="Sup">®</span> treatment <span class="Italics">[see also </span><span class="Italics"><a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight gain</span> has been observed in children and adolescents during treatment with RISPERDAL<span class="Sup">®</span>. Clinical monitoring of weight is recommended during treatment.</p>
<p>Data derive from short-term placebo-controlled trials and longer-term uncontrolled studies in pediatric patients (ages 5 to 17 years) with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, bipolar disorder, <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span>, or other psychiatric disorders. In the short-term trials (3 to 8 weeks), the mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> for RISPERDAL<span class="Sup">®</span>-treated patients was 2 kg, compared to 0.6 kg for placebo-treated patients. In these trials, approximately 33% of the RISPERDAL<span class="Sup">®</span> group had <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> ≥7%, compared to 7% in the placebo group. In longer-term, uncontrolled, open-label pediatric studies, the mean <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was 5.5 kg at Week 24 and 8 kg at Week 48 <span class="Italics">[see<a href="#S5.5"> Warnings and Precautions (5.5) </a>and<a href="#S6.1"> Adverse Reactions (6.1)</a>].</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></span></p>
<p><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> was frequently observed in placebo-controlled clinical trials of pediatric patients with <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span>. Most cases were mild or moderate in severity. These events were most often of early onset with peak incidence occurring during the first two weeks of treatment, and transient with a median duration of 16 days. <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> was the most commonly observed adverse reaction in the clinical trial of bipolar disorder in children and adolescents, as well as in the <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> trials in adolescents. As was seen in the <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span> trials, these adverse reactions were most often of early onset and transient in duration <span class="Italics">[see<a href="#S6.1"> Adverse Reactions (6.1 </a>and<a href="#S6.2"> 6.2)</a>]</span>. Patients experiencing persistent <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> may benefit from a change in dosing regimen <span class="Italics">[</span>see <span class="Italics"><a href="#S2.1">Dosage and Administration (2.1</a></span>, <span class="Italics"><a href="#S2.2">2.2</a></span>, <span class="Italics">and<a href="#S2.3"> 2.3)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030186" conceptname="Hyperprolactinemia">Hyperprolactinemia</span></span></p>
<p>RISPERDAL<span class="Sup">®</span> has been shown to elevate prolactin levels in children and adolescents as well as in adults <span class="Italics">[see </span><span class="Italics"><a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>. In double-blind, placebo-controlled studies of up to 8 weeks duration in children and adolescents (aged 5 to 17 years) with <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span> or psychiatric disorders other than <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span>, <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, or bipolar <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, 49% of patients who received  RISPERDAL<span class="Sup">®</span> had elevated prolactin levels compared to 2% of patients who received placebo. Similarly, in placebo-controlled trials in children and adolescents (aged 10 to 17 years) with bipolar disorder, or adolescents (aged 13 to 17 years) with <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, 82–87% of patients who received RISPERDAL<span class="Sup">®</span> had elevated levels of prolactin compared to 3–7% of patients on placebo. Increases were dose-dependent and generally greater in females than in males across indications.</p>
<p>In clinical trials in 1885 children and adolescents, <span class="product-label-link" type="condition" conceptid="79884" conceptname="Galactorrhea not associated with childbirth">galactorrhea</span> was reported in 0.8% of RISPERDAL<span class="Sup">®</span>-treated patients and <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span> was reported in 2.3% of RISPERDAL<span class="Sup">®</span>-treated patients.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Growth and Sexual Maturation</span></p>
<p>The long-term effects of RISPERDAL<span class="Sup">®</span> on growth and sexual maturation have not been fully evaluated in children and adolescents.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Juvenile Animal Studies</span></p>
<p>Juvenile dogs were treated for 40 weeks with oral risperidone doses of 0.31, 1.25, or 5 mg/kg/day. Decreased bone length and density were seen, with a no-effect dose of 0.31 mg/kg/day. This dose produced plasma levels (AUC) of risperidone plus its active metabolite paliperidone (9-hydroxy-risperidone) which were similar to those in children and adolescents receiving the maximum recommended human dose (MRHD) of 6 mg/day. In addition, a delay in sexual maturation was seen at all doses in both males and females. The above effects showed little or no reversibility in females after a 12 week drug-free recovery period.</p>
<p>In a study in which juvenile rats were treated with oral risperidone from days 12 to 50 of age, a reversible impairment of performance in a test of learning and memory was seen, in females only, with a no-effect dose of 0.63 mg/kg/day. This dose produced plasma levels (AUC) of risperidone plus paliperidone about half those observed in humans at the MRHD. No other consistent effects on neurobehavioral or reproductive development were seen up to the highest testable dose (1.25 mg/kg/day). This dose produced plasma levels (AUC) of risperidone plus paliperidone which were about two thirds of those observed in humans at the MRHD.</p>
<p>
 
</p>
<p></p>
<p>Clinical studies of RISPERDAL<span class="Sup">®</span> in the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> did not include sufficient numbers of patients aged 65 and over to determine whether or not they respond differently than younger patients. Other reported clinical experience has not identified differences in responses between elderly and younger patients. In general, a lower starting dose is recommended for an elderly patient, reflecting a decreased pharmacokinetic clearance in the elderly, as well as a greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy <span class="Italics">[see </span><span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3) </a></span><span class="Italics">and </span><span class="Italics"><a href="#S2.4">Dosage and Administration (2.4</a>, </span><span class="Italics"><a href="#S2.5">2.5)</a>]</span>. While elderly patients exhibit a greater tendency to <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, its risk in the elderly may be minimized by limiting the initial dose to 0.5 mg twice daily followed by careful titration <span class="Italics">[see </span><span class="Italics"><a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>. Monitoring of orthostatic vital signs should be considered in patients for whom this is of concern.</p>
<p>This drug is substantially excreted by the kidneys, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function <span class="Italics">[see </span><span class="Italics"><a href="#S2.4">Dosage and Administration (2.4)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>In patients with moderate to severe (Clcr 59 to 15 mL/min) <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, clearance of the sum of risperidone and its active metabolite decreased by 60%, compared to young healthy subjects. RISPERDAL<span class="Sup">®</span> doses should be reduced in patients with <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> <span class="Italics">[see </span><span class="Italics"><a href="#S2.4">Dosage and Administration (2.4)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>While the pharmacokinetics of risperidone in subjects with liver disease were comparable to those in young healthy subjects, the mean free fraction of risperidone in plasma was increased by about 35% because of the diminished concentration of both albumin and α<span class="Sub">1</span>-acid glycoprotein. RISPERDAL<span class="Sup">®</span> doses should be reduced in patients with liver disease <span class="Italics">[see </span><span class="Italics"><a href="#S2.4">Dosage and Administration (2.4) </a>and<a href="#S12.3"> Pharmacokinetics (12.3)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>Patients with Parkinson's Disease or <span class="product-label-link" type="condition" conceptid="4182210" conceptname="Dementia">Dementia</span> with Lewy Bodies can experience increased sensitivity to RISPERDAL<span class="Sup">®</span>. Manifestations can include <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">obtundation</span>, postural instability with frequent <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span>, <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>, and clinical features consistent with <span class="product-label-link" type="condition" conceptid="379802" conceptname="Neuroleptic malignant syndrome">neuroleptic malignant syndrome</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First"></p>
<p>RISPERDAL<span class="Sup">®</span> (risperidone) is not a controlled substance.</p>
<p>
 
</p>
<p></p>
<p>RISPERDAL<span class="Sup">®</span> has not been systematically studied in animals or humans for its potential for abuse. While the clinical trials did not reveal any tendency for any drug-seeking behavior, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, patients should be evaluated carefully for a history of drug abuse, and such patients should be observed closely for signs of RISPERDAL<span class="Sup">®</span> misuse or abuse (e.g., development of tolerance, increases in dose, drug-seeking behavior).</p>
<p>
 
</p>
<p></p>
<p>RISPERDAL<span class="Sup">®</span> has not been systematically studied in animals or humans for its potential for tolerance or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"></p>
<p>Premarketing experience included eight reports of acute RISPERDAL<span class="Sup">®</span> overdosage with estimated doses ranging from 20 to 300 mg and no fatalities. In general, reported signs and symptoms were those resulting from an exaggeration of the drug's known pharmacological effects, i.e., <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> and sedation, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>. One case, involving an estimated <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of 240 mg, was associated with <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, prolonged QT, and widened QRS. Another case, involving an estimated <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of 36 mg, was associated with a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>.</p>
<p>Postmarketing experience includes reports of acute RISPERDAL<span class="Sup">®</span> overdosage, with estimated doses of up to 360 mg. In general, the most frequently reported signs and symptoms are those resulting from an exaggeration of the drug's known pharmacological effects, i.e., <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, sedation, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="373747" conceptname="Extrapyramidal disease">extrapyramidal symptoms</span>. Other adverse reactions reported since market introduction related to RISPERDAL<span class="Sup">®</span> <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> include prolonged QT interval and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de pointes</span> has been reported in association with combined <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of RISPERDAL<span class="Sup">®</span> and paroxetine.</p>
<p>
 
</p>
<p></p>
<p>For the most up to date information on the management of RISPERDAL<span class="Sup">®</span> overdosage, contact a certified poison control center (1-800-222-1222 or www.poison.org). Provide supportive care including close medical supervision and monitoring. Treatment should consist of general measures employed in the management of overdosage with any drug. Consider the possibility of multiple drug overdosage. Ensure an adequate airway, oxygenation, and ventilation. Monitor cardiac rhythm and vital signs. Use supportive and symptomatic measures. There is no specific  antidote to RISPERDAL<span class="Sup">®</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-11"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>RISPERDAL<span class="Sup">®</span> contains risperidone, an atypical antipsychotic belonging to the chemical class of benzisoxazole derivatives. The chemical designation is 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one. Its molecular formula is C<span class="Sub">23</span>H<span class="Sub">27</span>FN<span class="Sub">4</span>O<span class="Sub">2</span> and its molecular weight is 410.49. The structural formula is:</p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ccb70f90-9ef1-4eac-925f-0178cacdac6b&amp;name=MM1.jpg"></p>
<p>Risperidone is a white to slightly beige powder. It is practically insoluble in water, freely soluble in methylene chloride, and soluble in methanol and 0.1 <span class="Underline">N</span> HCl.</p>
<p>RISPERDAL<span class="Sup">®</span> Tablets are for oral administration and available in 0.25 mg (dark yellow), 0.5 mg (red-brown), 1 mg (white), 2 mg (orange), 3 mg (yellow), and 4 mg (green) strengths. RISPERDAL<span class="Sup">®</span> tablets contain the following inactive ingredients: colloidal silicon dioxide, hypromellose, lactose, magnesium stearate, microcrystalline cellulose, propylene glycol, sodium lauryl sulfate, and starch (corn). The 0.25 mg, 0.5 mg, 2 mg, 3 mg, and 4 mg tablets also contain talc and titanium dioxide. The 0.25 mg tablets contain yellow iron oxide; the 0.5 mg tablets contain red iron oxide; the 2 mg tablets contain FD&amp;C Yellow No. 6 Aluminum Lake; the 3 mg and 4 mg tablets contain D&amp;C Yellow No. 10; the 4 mg tablets contain FD&amp;C Blue No. 2 Aluminum Lake.</p>
<p>RISPERDAL<span class="Sup">®</span> is also available as a 1 mg/mL oral solution. RISPERDAL<span class="Sup">®</span> Oral Solution contains the following inactive ingredients: tartaric acid, benzoic acid, sodium hydroxide, and purified water.</p>
<p>RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablets are available in 0.5 mg (light coral), 1 mg (light coral), 2 mg (coral), 3 mg (coral), and 4 mg (coral) strengths. RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablets contain the following inactive ingredients: Amberlite<span class="Sup">®</span> resin, gelatin, mannitol, glycine, simethicone, carbomer, sodium hydroxide, aspartame, red ferric oxide, and peppermint oil. In addition, the 2 mg, 3 mg, and 4 mg RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablets contain xanthan gum.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-12"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>The mechanism of action of RISPERDAL<span class="Sup">®</span>, in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, is unknown. However, it has been proposed that the drug's therapeutic activity in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> could be mediated through a combination of dopamine Type 2 (D<span class="Sub">2</span>) and serotonin Type 2 (5HT<span class="Sub">2</span>) receptor antagonism. The clinical effect from RISPERDAL<span class="Sup">®</span> results from the combined concentrations of risperidone and its major metabolite, 9-hydroxyrisperidone <span class="Italics">[see </span><span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>. Antagonism at receptors other than D<span class="Sub">2</span> and 5HT<span class="Sub">2</span><span class="Italics"> [see </span><span class="Italics"><a href="#S12.1">Clinical Pharmacology (12.1)</a>] </span>may explain some of the other effects of RISPERDAL<span class="Sup">®</span>.</p>
<p>
 
</p>
<p></p>
<p>RISPERDAL<span class="Sup">®</span> is a selective monoaminergic antagonist with high affinity (Ki of 0.12 to 7.3 nM) for the serotonin Type 2 (5HT<span class="Sub">2</span>), dopamine Type 2 (D<span class="Sub">2</span>), α<span class="Sub">1</span> and α<span class="Sub">2</span> adrenergic, and H<span class="Sub">1</span> histaminergic receptors. RISPERDAL<span class="Sup">®</span> acts as an antagonist at other receptors, but with lower potency. RISPERDAL<span class="Sup">®</span> has low to moderate affinity (Ki of 47 to 253 nM) for the serotonin 5HT<span class="Sub">1C</span>, 5HT<span class="Sub">1D</span>, and 5HT<span class="Sub">1A</span> receptors, weak affinity (Ki of 620 to 800 nM) for the dopamine D<span class="Sub">1</span> and haloperidol-sensitive sigma site, and no affinity (when tested at concentrations &gt;10<span class="Sup">-5</span> M) for cholinergic muscarinic or β<span class="Sub">1</span> and β<span class="Sub">2</span> adrenergic receptors.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Absorption</span></p>
<p>Risperidone is well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.</p>
<p>Pharmacokinetic studies showed that RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablets and RISPERDAL<span class="Sup">®</span> Oral Solution are bioequivalent to RISPERDAL<span class="Sup">®</span> Tablets.</p>
<p>Plasma concentrations of risperidone, its major metabolite, 9-hydroxyrisperidone, and risperidone plus 9-hydroxyrisperidone are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily). Following oral administration of solution or tablet, mean peak plasma concentrations of risperidone occurred at about 1 hour. Peak concentrations of 9-hydroxyrisperidone occurred at about 3 hours in extensive metabolizers, and 17 hours in poor metabolizers. Steady-state concentrations of risperidone are reached in 1 day in extensive metabolizers and would be expected to reach steady-state in about 5 days in poor metabolizers. Steady-state concentrations of 9-hydroxyrisperidone are reached in 5–6 days (measured in extensive metabolizers).</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Food Effect</span></p>
<p>Food does not affect either the rate or extent of absorption of risperidone. Thus, RISPERDAL<span class="Sup">®</span> can be given with or without meals.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Distribution</span></p>
<p>Risperidone is rapidly distributed. The volume of distribution is 1–2 L/kg. In plasma, risperidone is bound to albumin and α<span class="Sub">1</span>-acid glycoprotein. The plasma protein binding of risperidone is 90%, and that of its major metabolite, 9-hydroxyrisperidone, is 77%. Neither risperidone nor 9-hydroxyrisperidone displaces each other from plasma binding sites. High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Metabolism</span></p>
<p>Risperidone is extensively metabolized in the liver. The main metabolic pathway is through hydroxylation of risperidone to 9-hydroxyrisperidone by the enzyme, CYP 2D6. A minor metabolic pathway is through <span class="Italics">N</span>-dealkylation. The main metabolite, 9-hydroxyrisperidone, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug results from the combined concentrations of risperidone plus 9-hydroxyrisperidone.</p>
<p>CYP 2D6, also called debrisoquin hydroxylase, is the enzyme responsible for metabolism of many neuroleptics, antidepressants, antiarrhythmics, and other drugs. CYP 2D6 is subject to genetic polymorphism (about 6%–8% of Caucasians, and a very low percentage of Asians, have little or no activity and are "poor metabolizers") and to inhibition by a variety of substrates and some non-substrates, notably quinidine. Extensive CYP 2D6 metabolizers convert risperidone rapidly into 9-hydroxyrisperidone, whereas poor CYP 2D6 metabolizers convert it much more slowly. Although extensive metabolizers have lower risperidone and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, are similar in extensive and poor metabolizers.</p>
<p>Risperidone could be subject to two kinds of drug-drug interactions. First, inhibitors of CYP 2D6 interfere with conversion of risperidone to 9-hydroxyrisperidone<span class="Italics"> [see </span><span class="Italics"><a href="#S7">Drug Interactions (7)</a>]</span>. This occurs with quinidine, giving essentially all recipients a risperidone pharmacokinetic profile typical of poor metabolizers. The therapeutic benefits and adverse effects of risperidone in patients receiving quinidine have not been evaluated, but observations in a modest number (n≅70) of poor metabolizers given RISPERDAL<span class="Sup">®</span> do not suggest important differences between poor and extensive metabolizers. Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with RISPERDAL<span class="Sup">®</span> may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone <span class="Italics">[see </span><span class="Italics"><a href="#S7">Drug Interactions (7)</a>]</span>. It would also be possible for risperidone to interfere with metabolism of other drugs metabolized by CYP 2D6. Relatively weak binding of risperidone to the enzyme suggests this is unlikely <span class="Italics">[see </span><span class="Italics"><a href="#S7">Drug Interactions (7)</a>]</span>.</p>
<p><span class="Italics">In vitro</span> studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6. Therefore, RISPERDAL<span class="Sup">®</span> is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway. In drug interaction studies, RISPERDAL<span class="Sup">®</span> did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.</p>
<p><span class="Italics">In vitro</span> studies demonstrated that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Excretion</span></p>
<p>Risperidone and its metabolites are eliminated via the urine and, to a much lesser extent, via the feces. As illustrated by a <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance study of a single 1 mg oral dose of 14C-risperidone administered as solution to three healthy male volunteers, total recovery of radioactivity at 1 week was 84%, including 70% in the urine and 14% in the feces.</p>
<p>The apparent half-life of risperidone was 3 hours (CV=30%) in extensive metabolizers and 20 hours (CV=40%) in poor metabolizers. The apparent half-life of 9-hydroxyrisperidone was about 21 hours (CV=20%) in extensive metabolizers and 30 hours (CV=25%) in poor metabolizers. The pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, were similar in extensive and poor metabolizers, with an overall mean elimination half-life of about 20 hours.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Drug-Drug Interaction Studies</span></p>
<p><span class="Italics">[See<a href="#S7"> Drug Interactions (7)</a>].</span></p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Specific Populations</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p><span class="Italics">[See<a href="#S8.6"> Use in Specific Populations (8.6 </a>and<a href="#S8.7"> 8.7)</a>].</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Elderly</span></p>
<p>In healthy elderly subjects, renal clearance of both risperidone and 9-hydroxyrisperidone was decreased, and elimination half-lives were prolonged compared to young healthy subjects. Dosing should be modified accordingly in the elderly patients <span class="Italics">[see </span><span class="Italics"><a href="#S8.5">Use in Specific Populations (8.5)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Pediatric</span></p>
<p>The pharmacokinetics of risperidone and 9-hydroxyrisperidone in children were similar to those in adults after correcting for the difference in body weight.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Race and Gender Effects</span></p>
<p>No specific pharmacokinetic study was conducted to investigate race and gender effects, but a population pharmacokinetic analysis did not identify important differences in the disposition of risperidone due to gender (whether corrected for body weight or not) or race.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-13"></a><p></p>
<h1>NONCLINICAL TOXICOLOGY</h1>
<p class="First"></p>
<p><span class="Underline">Carcinogenesis</span></p>
<p>Carcinogenicity studies were conducted in Swiss albino mice and Wistar rats. Risperidone was administered in the diet at doses of 0.63 mg/kg, 2.5 mg/kg, and 10 mg/kg for 18 months to mice and for 25 months to rats. These doses are equivalent to approximately 2, 9, and 38 times the maximum recommended human dose (MRHD) for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> of 16 mg/day on a mg/kg basis or 0.2, 0.75, and 3 times the MRHD (mice) or 0.4, 1.5, and 6 times the MRHD (rats) on a mg/m<span class="Sup">2</span> body surface basis. A maximum tolerated dose was not achieved in male mice. There were statistically significant increases in pituitary gland <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>, endocrine pancreas <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span>, and mammary gland adenocarcinomas. The table below summarizes the multiples of the human dose on a mg/m<span class="Sup">2</span> (mg/kg) basis at which these tumors occurred.</p>
<table width="100%">
<col align="left" span="1" valign="top" width="35%">
<col align="center" span="1" valign="top" width="15%">
<col align="center" span="1" valign="top" width="15%">
<col align="center" span="1" valign="top" width="15%">
<col align="center" span="1" valign="top" width="20%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="3"></th>
<th align="center" colspan="2">Multiples of Maximum Human Dose in mg/m<span class="Sup">2</span> (mg/kg)</th>
</tr>
<tr>
<th align="left" colspan="1">Tumor Type</th>
<th align="center" colspan="1">Species</th>
<th align="center" colspan="1">Sex</th>
<th align="center" colspan="1">Lowest Effect Level</th>
<th align="center" colspan="1">Highest No-Effect Level</th>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">Pituitary adenomas</span></td>
<td align="center">mouse</td>
<td align="center">female</td>
<td align="center">0.75 (9.4)</td>
<td align="center">0.2 (2.4)</td>
</tr>
<tr>
<td align="left">Endocrine pancreas <span class="product-label-link" type="condition" conceptid="4106411" conceptname="Adenofibroma">adenomas</span></td>
<td align="center">rat</td>
<td align="center">male</td>
<td align="center">1.5 (9.4)</td>
<td align="center">0.4 (2.4)</td>
</tr>
<tr>
<td align="left">Mammary gland adenocarcinomas</td>
<td align="center">mouse</td>
<td align="center">female</td>
<td align="center">0.2 (2.4)</td>
<td align="center">none</td>
</tr>
<tr>
<td align="left"></td>
<td align="center">rat</td>
<td align="center">female</td>
<td align="center">0.4 (2.4)</td>
<td align="center">none</td>
</tr>
<tr>
<td align="left"></td>
<td align="center">rat</td>
<td align="center">male</td>
<td align="center">6.0 (37.5)</td>
<td align="center">1.5 (9.4)</td>
</tr>
<tr class="Last">
<td align="left">Mammary gland neoplasm, Total</td>
<td align="center">rat</td>
<td align="center">male</td>
<td align="center">1.5 (9.4)</td>
<td align="center">0.4 (2.4)</td>
</tr>
</tbody>
</table>
<p>Antipsychotic drugs have been shown to chronically elevate prolactin levels in rodents. Serum prolactin levels were not measured during the risperidone carcinogenicity studies; however, measurements during subchronic toxicity studies showed that risperidone elevated serum prolactin levels 5–6 fold in mice and rats at the same doses used in the carcinogenicity studies. An increase in mammary, pituitary, and endocrine pancreas neoplasms has been found in rodents after chronic administration of other antipsychotic drugs and is considered to be prolactin-mediated. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is unknown <span class="Italics">[see </span><span class="Italics"><a href="#S5.6">Warnings and Precautions (5.6)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Mutagenesis</span></p>
<p>No evidence of mutagenic or clastogenic potential for risperidone was found in the Ames gene mutation test, the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, the <span class="Italics">in vitro</span> rat hepatocyte DNA-repair assay, the <span class="Italics">in vivo</span> micronucleus test in mice, the sex-linked recessive lethal test in <span class="Italics">Drosophila</span>, or the chromosomal aberration test in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> or Chinese hamster ovary cells.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Impairment of Fertility</span></p>
<p>Risperidone (0.16 to 5 mg/kg) was shown to impair mating, but not fertility, in Wistar rats in three reproductive studies (two Segment I and a multigenerational study) at doses 0.1 to 3 times the maximum recommended human dose (MRHD) on a mg/m<span class="Sup">2</span> body surface area basis. The effect appeared to be in females, since impaired mating behavior was not noted in the Segment I study in which males only were treated. In a subchronic study in Beagle dogs in which risperidone was administered orally at doses of 0.31 to 5 mg/kg, sperm motility and concentration were decreased at doses 0.6 to 10 times the MRHD on a mg/m<span class="Sup">2</span> body surface area basis. Dose-related decreases were also noted in serum testosterone at the same doses. Serum testosterone and sperm parameters partially recovered, but remained decreased after treatment was discontinued. A no-effect dose could not be determined in either rat or dog.</p>
<p>
 
</p>
<p></p>
<p>Juvenile dogs were treated for 40 weeks with oral risperidone doses of 0.31, 1.25, or 5 mg/kg/day. Decreased bone length and density were observed with a no-effect dose of 0.31 mg/kg/day. This dose produced plasma AUC levels of risperidone plus its active metabolite paliperidone (9-hydroxy-risperidone) which were similar to those in children and adolescents receiving the maximum recommended human dose (MRHD) of 6 mg/day. In addition, a delay in sexual maturation was seen at all doses in both males and females. The above effects showed little or no reversibility in females after a 12 week drug-free recovery period.</p>
<p>In a study in which juvenile rats were treated with oral risperidone from days 12 to 50 of age, a reversible impairment of performance in a test of learning and memory was observed in females only with a no-effect dose of 0.63 mg/kg/day. This dose produced plasma AUC levels of risperidone plus paliperidone about half those observed in humans at the MRHD. No other consistent effects on neurobehavioral or reproductive development were seen up to the highest testable dose of 1.25 mg/kg/day. This dose produced plasma AUC levels of risperidone plus paliperidone which were about two thirds of those observed in humans at the MRHD.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-14"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"></p>
<p><span class="Underline">Adults</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Short-Term Efficacy</span></p>
<p>The efficacy of RISPERDAL<span class="Sup">®</span> in the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> was established in four short-term (4- to 8-week) controlled trials of <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> inpatients who met DSM-III-R criteria for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>.</p>
<p>Several instruments were used for assessing psychiatric signs and symptoms in these studies, among them the Brief Psychiatric Rating Scale (BPRS), a multi-item inventory of general psychopathology traditionally used to evaluate the effects of drug treatment in <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>. The BPRS <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> cluster (conceptual disorganization, hallucinatory behavior, suspiciousness, and unusual thought content) is considered a particularly useful subset for assessing actively <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> schizophrenic patients. A second traditional assessment, the Clinical Global Impression (CGI), reflects the impression of a skilled observer, fully familiar with the manifestations of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>, about the overall clinical state of the patient. In addition, the Positive and Negative Syndrome Scale (PANSS) and the Scale for Assessing Negative Symptoms (SANS) were employed.</p>
<p>The results of the trials follow:</p>
<p>(1)In a 6-week, placebo-controlled trial (n=160) involving titration of RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p> in doses up to 10 mg/day (twice-daily schedule), RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p> was generally superior to placebo on the BPRS total score, on the BPRS <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> cluster, and marginally superior to placebo on the SANS.(2)In an 8-week, placebo-controlled trial (n=513) involving 4 fixed doses of RISPERDAL</p>
<p><span class="Sup">® </span></p>
<p>(2 mg/day, 6 mg/day, 10 mg/day, and 16 mg/day, on a twice-daily schedule), all 4 RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p> groups were generally superior to placebo on the BPRS total score, BPRS <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> cluster, and CGI severity score; the 3 highest RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p> dose groups were generally superior to placebo on the PANSS negative subscale. The most consistently positive responses on all measures were seen for the 6 mg dose group, and there was no suggestion of increased benefit from larger doses.(3)In an 8-week, dose comparison trial (n=1356) involving 5 fixed doses of RISPERDAL</p>
<p><span class="Sup">® </span></p>
<p>(1 mg/day, 4 mg/day, 8 mg/day, 12 mg/day, and 16 mg/day, on a twice-daily schedule), the four highest RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p> dose groups were generally superior to the 1 mg RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p> dose group on BPRS total score, BPRS <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> cluster, and CGI severity score. None of the dose groups were superior to the 1 mg group on the PANSS negative subscale. The most consistently positive responses were seen for the 4 mg dose group.(4)In a 4-week, placebo-controlled dose comparison trial (n=246) involving 2 fixed doses of RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p> (4 and 8 mg/day on a once-daily schedule), both RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p> dose groups were generally superior to placebo on several PANSS measures, including a response measure (&gt;20% reduction in PANSS total score), PANSS total score, and the BPRS <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span> cluster (derived from PANSS). The results were generally stronger for the 8 mg than for the 4 mg dose group.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Long-Term Efficacy</span></p>
<p>In a longer-term trial, 365 adult outpatients predominantly meeting DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and who had been clinically stable for at least 4 weeks on an antipsychotic medication were randomized to RISPERDAL<span class="Sup">®</span> (2–8 mg/day) or to an active comparator, for 1 to 2 years of observation for relapse. Patients receiving RISPERDAL<span class="Sup">®</span> experienced a significantly longer time to relapse over this time period compared to those receiving the active comparator.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Pediatrics</span></p>
<p>The efficacy of RISPERDAL<span class="Sup">®</span> in the treatment of <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> in adolescents aged 13–17 years was demonstrated in two short-term (6 and 8 weeks), double-blind controlled trials. All patients met DSM-IV diagnostic criteria for <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span> and were experiencing an acute episode at time of enrollment. In the first trial (study #1), patients were randomized into one of three treatment groups: RISPERDAL<span class="Sup">®</span> 1–3 mg/day (n = 55, mean modal dose = 2.6 mg), RISPERDAL<span class="Sup">®</span> 4–6 mg/day (n = 51, mean modal dose = 5.3 mg), or placebo (n = 54). In the second trial (study #2), patients were randomized to either RISPERDAL<span class="Sup">®</span> 0.15–0.6 mg/day (n = 132, mean modal dose = 0.5 mg) or RISPERDAL<span class="Sup">®</span> 1.5–6 mg/day (n = 125, mean modal dose = 4 mg). In all cases, study medication was initiated at 0.5 mg/day (with the exception of the 0.15–0.6 mg/day group in study #2, where the initial dose was 0.05 mg/day) and titrated to the target dosage range by approximately Day 7. Subsequently, dosage was increased to the maximum tolerated dose within the target dose range by Day 14. The primary efficacy variable in all studies was the mean change from baseline in total PANSS score.</p>
<p>Results of the studies demonstrated efficacy of RISPERDAL<span class="Sup">®</span> in all dose groups from 1–6 mg/day compared to placebo, as measured by significant reduction of total PANSS score. The efficacy on the primary parameter in the 1–3 mg/day group was comparable to the 4–6 mg/day group in study #1, and similar to the efficacy demonstrated in the 1.5–6 mg/day group in study #2. In study #2, the efficacy in the 1.5–6 mg/day group was statistically significantly greater than that in the 0.15–0.6 mg/day group. Doses higher than 3 mg/day did not reveal any trend towards greater efficacy.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Adults</span></p>
<p>The efficacy of RISPERDAL<span class="Sup">®</span> in the treatment of acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes was established in two short-term (3-week) placebo-controlled trials in patients who met the DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span> with <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes. These trials included patients with or without <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> features.</p>
<p>The primary rating instrument used for assessing <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptoms in these trials was the Young <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">Mania</span> Rating Scale (YMRS), an 11-item clinician-rated scale traditionally used to assess the degree of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> symptomatology (<span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, disruptive/<span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span>, sleep, <span class="product-label-link" type="condition" conceptid="4304866" conceptname="Elevated mood">elevated mood</span>, speech, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">increased activity</span>, sexual interest, language/thought disorder, thought content, appearance, and insight) in a range from 0 (no <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> features) to 60 (maximum score). The primary outcome in these trials was change from baseline in the YMRS total score. The results of the trials follow:</p>
<p>(1)In one 3-week placebo-controlled trial (n=246), limited to patients with <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic episodes</span>, which involved a dose range of RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p> 1–6 mg/day, once daily, starting at 3 mg/day (mean modal dose was 4.1 mg/day), RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p> was superior to placebo in the reduction of YMRS total score.(2)In another 3-week placebo-controlled trial (n=286), which involved a dose range of 1–6 mg/day, once daily, starting at 3 mg/day (mean modal dose was 5.6 mg/day), RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p> was superior to placebo in the reduction of YMRS total score.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Pediatrics</span></p>
<p>The efficacy of RISPERDAL<span class="Sup">®</span> in the treatment of <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span> in children or adolescents with <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I disorder</span> was demonstrated in a 3-week, randomized, double-blind, placebo-controlled, multicenter trial including patients ranging in ages from 10 to 17 years who were experiencing a <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episode of <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">bipolar I disorder</span>. Patients were randomized into one of three treatment groups: RISPERDAL<span class="Sup">®</span> 0.5–2.5 mg/day (n = 50, mean modal dose = 1.9 mg), RISPERDAL<span class="Sup">®</span> 3–6 mg/day (n = 61, mean modal dose = 4.7 mg), or placebo (n = 58). In all cases, study medication was initiated at 0.5 mg/day and titrated to the target dosage range by Day 7, with further increases in dosage to the maximum tolerated dose within the targeted dose range by Day 10. The primary rating instrument used for assessing efficacy in this study was the mean change from baseline in the total YMRS score.</p>
<p>Results of this study demonstrated efficacy of RISPERDAL<span class="Sup">®</span> in both dose groups compared with placebo, as measured by significant reduction of total YMRS score. The efficacy on the primary parameter in the 3–6 mg/day dose group was comparable to the 0.5–2.5 mg/day dose group. Doses higher than 2.5 mg/day did not reveal any trend towards greater efficacy.</p>
<p>
 
</p>
<p></p>
<p>The efficacy of RISPERDAL<span class="Sup">®</span> with concomitant lithium or valproate in the treatment of acute <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed episodes was established in one controlled trial in adult patients who met the DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="432876" conceptname="Bipolar I disorder">Bipolar I Disorder</span>. This trial included patients with or without <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> features and with or without a rapid-cycling course.</p>
<p>(1)In this 3-week placebo-controlled combination trial, 148 in- or outpatients on lithium or valproate therapy with inadequately controlled <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed symptoms were randomized to receive RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p>, placebo, or an active comparator, in combination with their original therapy. RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p>, in a dose range of 1–6 mg/day, once daily, starting at 2 mg/day (mean modal dose of 3.8 mg/day), combined with lithium or valproate (in a therapeutic range of 0.6 mEq/L to 1.4 mEq/L or 50 mcg/mL to 120 mcg/mL, respectively) was superior to lithium or valproate alone in the reduction of YMRS total score.(2)In a second 3-week placebo-controlled combination trial, 142 in- or outpatients on lithium, valproate, or carbamazepine therapy with inadequately controlled <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic</span> or mixed symptoms were randomized to receive RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p> or placebo, in combination with their original therapy. RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p>, in a dose range of 1–6 mg/day, once daily, starting at 2 mg/day (mean modal dose of 3.7 mg/day), combined with lithium, valproate, or carbamazepine (in therapeutic ranges of 0.6 mEq/L to 1.4 mEq/L for lithium, 50 mcg/mL to 125 mcg/mL for valproate, or 4–12 mcg/mL for carbamazepine, respectively) was not superior to lithium, valproate, or carbamazepine alone in the reduction of YMRS total score. A possible explanation for the failure of this trial was induction of risperidone and 9-hydroxyrisperidone clearance by carbamazepine, leading to subtherapeutic levels of risperidone and 9-hydroxyrisperidone.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Short-Term Efficacy</span></p>
<p>The efficacy of RISPERDAL<span class="Sup">®</span> in the treatment of <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> associated with <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span> was established in two 8-week, placebo-controlled trials in children and adolescents (aged 5 to 16 years) who met the DSM-IV criteria for <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span>. Over 90% of these subjects were under 12 years of age and most weighed over 20 kg (16–104.3 kg).</p>
<p>Efficacy was evaluated using two assessment scales: the Aberrant Behavior Checklist (ABC) and the Clinical Global Impression - Change (CGI-C) scale. The primary outcome measure in both trials was the change from baseline to endpoint in the <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span> subscale of the ABC (ABC-I). The ABC-I subscale measured the emotional and behavioral symptoms of <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autism</span>, including <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span> towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. The CGI-C rating at endpoint was a co-primary outcome measure in one of the studies.</p>
<p>The results of these trials are as follows:</p>
<p>(1)In one of the 8-week, placebo-controlled trials, children and adolescents with <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span> (n=101), aged 5 to 16 years, received twice daily doses of placebo or RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p> 0.5–3.5 mg/day on a weight-adjusted basis. RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p>, starting at 0.25 mg/day or 0.5 mg/day depending on baseline weight (&lt; 20 kg and ≥ 20 kg, respectively) and titrated to clinical response (mean modal dose of 1.9 mg/day, equivalent to 0.06 mg/kg/day), significantly improved scores on the ABC-I subscale and on the CGI-C scale compared with placebo.(2)In the other 8-week, placebo-controlled trial in children with <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span> (n=55), aged 5 to 12 years, RISPERDAL</p>
<p><span class="Sup">®</span></p>
<p> 0.02 to 0.06 mg/kg/day given once or twice daily, starting at 0.01 mg/kg/day and titrated to clinical response (mean modal dose of 0.05 mg/kg/day, equivalent to 1.4 mg/day), significantly improved scores on the ABC-I subscale compared with placebo.</p>
<p>A third trial was a 6-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of a lower than recommended dose of risperidone in subjects (N=96) 5 to 17 years of age with <span class="product-label-link" type="condition" conceptid="439780" conceptname="Autistic disorder">autistic disorder</span> (defined by DSM-IV criteria) and associated <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> and related behavioral symptoms. Approximately 77% of patients were younger than 12 years of age (mean age = 9), and 88% were male. Most patients (73%) weighed less than 45 kg (mean weight = 40 kg). Approximately 90% of patients were antipsychotic-naïve before entering the study.</p>
<p>There were two weight-based, fixed doses of risperidone (high-dose and low-dose). The high dose was 1.25 mg per day for patients weighing 20 to &lt; 45 kg, and it was 1.75 mg per day for patients weighing ≥ 45 kg. The low dose was 0.125 mg per day for patients weighing 20 to &lt; 45 kg, and it was 0.175 mg per day for patients weighing ≥ 45 kg. The dose was administered once daily in the morning, or in the evening if sedation occurred.</p>
<p>The primary efficacy endpoint was the mean change in the Aberrant Behavior Checklist – <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">Irritability</span> subscale (ABC-I) score from baseline to the end of Week 6. The study demonstrated the efficacy of high-dose risperidone, as measured by the mean change in ABC-I score. It did not demonstrate efficacy for low-dose risperidone. The mean baseline ABC-I scores were 29 in the placebo group (n = 35), 27 in the risperidone low-dose group (n = 30), and 28 in the risperidone high-dose group (n = 31). The mean changes in ABC-I scores were -3.5, -7.4, and -12.4 in the placebo, low-dose, and high-dose group respectively. The results in the high-dose group were statistically significant (p&lt; 0.001) but not in the low-dose group (p=0.164).</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Long-Term Efficacy</span></p>
<p>Following completion of the first 8-week double-blind study, 63 patients entered an open-label study extension where they were treated with RISPERDAL<span class="Sup">®</span> for 4 or 6 months (depending on whether they received RISPERDAL<span class="Sup">®</span> or placebo in the double-blind study). During this open-label treatment period, patients were maintained on a mean modal dose of RISPERDAL<span class="Sup">®</span> of 1.8–2.1 mg/day (equivalent to 0.05 – 0.07 mg/kg/day).</p>
<p>Patients who maintained their positive response to RISPERDAL<span class="Sup">®</span> (response was defined as ≥ 25% improvement on the ABC-I subscale and a CGI-C rating of 'much improved' or 'very much improved') during the 4–6 month open-label treatment phase for about 140 days, on average, were randomized to receive RISPERDAL<span class="Sup">®</span> or placebo during an 8-week, double-blind withdrawal study (n=39 of the 63 patients). A pre-planned interim analysis of data from patients who completed the withdrawal study (n=32), undertaken by an independent Data Safety Monitoring Board, demonstrated a significantly lower relapse rate in the RISPERDAL<span class="Sup">®</span> group compared with the placebo group. Based on the interim analysis results, the study was terminated due to demonstration of a statistically significant effect on relapse prevention. Relapse was defined as ≥ 25% worsening on the most recent assessment of the ABC-I subscale (in relation to baseline of the randomized withdrawal phase).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p><span class="Underline">RISPERDAL<span class="Sup">®</span> (risperidone) Tablets</span></p>
<p>RISPERDAL<span class="Sup">®</span> (risperidone) Tablets are imprinted <span class="Sup">"</span>JANSSEN<span class="Sup">"</span> on one side and either  "Ris 0.25", "Ris 0.5", "R1", "R2", "R3", or "R4" according to their respective strengths.</p>
<p>0.25 mg dark yellow, capsule-shaped tablets: bottles of 60 NDC 50458-301-04, bottles of 500 NDC 50458-301-50, and hospital unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs of 100 NDC 50458-301-01.</p>
<p>0.5 mg red-brown, capsule-shaped tablets: bottles of 60 NDC 50458-302-06, bottles of 500 NDC 50458-302-50, and hospital unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs of 100 NDC 50458-302-01.</p>
<p>1 mg white, capsule-shaped tablets: bottles of 60 NDC 50458-300-06, bottles of 500 NDC 50458-300-50, and hospital unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs of 100 NDC 50458-300-01.</p>
<p>2 mg orange, capsule-shaped tablets: bottles of 60 NDC 50458-320-06, bottles of 500 NDC 50458-320-50, and hospital unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs of 100 NDC 50458-320-01.</p>
<p>3 mg yellow, capsule-shaped tablets: bottles of 60 NDC 50458-330-06, bottles of 500 NDC 50458-330-50, and hospital unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs of 100 NDC 50458-330-01.</p>
<p>4 mg green, capsule-shaped tablets: bottles of 60 NDC 50458-350-06 and hospital unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs of 100 NDC 50458-350-01.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">RISPERDAL<span class="Sup">®</span> (risperidone) Oral Solution</span></p>
<p>RISPERDAL<span class="Sup">®</span> (risperidone) 1 mg/mL Oral Solution (NDC 50458-305-03) is supplied in 30 mL bottles with a calibrated (in milligrams and milliliters) pipette. The minimum calibrated volume is 0.25 mL, while the maximum calibrated volume is 3 mL.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> (risperidone) Orally Disintegrating Tablets</span></p>
<p>RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> (risperidone) Orally Disintegrating Tablets are etched on one side with "R0.5", "R1", "R2", "R3", or "R4" according to their respective strengths. RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablets 0.5 mg, 1 mg, and 2 mg are packaged in <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packs of 4 (2 × 2) tablets. Orally Disintegrating Tablets 3 mg and 4 mg are packaged in a child-resistant pouch containing a <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> with 1 tablet.</p>
<p>0.5 mg light coral, round, biconvex tablets: 7 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages (4 tablets each) per box, NDC 50458-395-28, and long-term care <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packaging of 30 tablets NDC 50458-395-30.</p>
<p>1 mg light coral, square, biconvex tablets: 7 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages (4 tablets each) per box, NDC 50458-315-28, and long-term care <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packaging of 30 tablets NDC 50458-315-30.</p>
<p>2 mg coral, square, biconvex tablets: 7 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages (4 tablets each) per box, NDC 50458-325-28.</p>
<p>3 mg coral, round, biconvex tablets: 28 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> per box, NDC 50458-335-28.</p>
<p>4 mg coral, round, biconvex tablets: 28 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> per box, NDC 50458-355-28.</p>
<p>
 
</p>
<p></p>
<p>RISPERDAL<span class="Sup">®</span> Tablets should be stored at controlled room temperature 15°–25°C (59°–77°F). Protect from light and moisture.</p>
<p>RISPERDAL<span class="Sup">®</span> 1 mg/mL Oral Solution should be stored at controlled room temperature 15°–25°C (59°–77°F). Protect from light and freezing.</p>
<p>RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablets should be stored at controlled room temperature 15°–25°C (59°–77°F).</p>
<p>Keep out of reach of children.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1>INFORMATION FOR PATIENTS</h1>
<p class="First"></p>
<p>Physicians are advised to discuss the following issues with patients for whom they prescribe RISPERDAL<span class="Sup">®</span> and their caregivers:</p>
<p>
 
</p>
<p></p>
<p>Advise patients and caregivers about the risk of <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, especially during the period of initial dose titration <span class="Italics">[see </span><span class="Italics"><a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>Inform patients and caregivers that RISPERDAL<span class="Sup">®</span> has the potential to impair judgment, thinking, or motor skills. Advise caution about operating hazardous machinery, including automobiles, until patients are reasonably certain that RISPERDAL<span class="Sup">®</span> therapy does not affect them adversely <span class="Italics">[see </span><span class="Italics"><a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>Advise patients and caregivers to notify their physician if the patient becomes pregnant or intends to become pregnant during therapy<span class="Italics"> [see </span><span class="Italics"><a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>Inform patients and caregivers that risperidone and its active metabolite are present in human breast milk; there is a potential for serious adverse reactions from RISPERDAL in nursing infants. Advise patients that the decision whether to discontinue nursing or to discontinue the RISPERDAL<span class="Sup">®</span> should take into account the importance of the drug to the patient <span class="Italics">[see </span><span class="Italics"><a href="#S8.3">Use in Specific Populations (8.3)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>Advise patients and caregivers to inform their physicians if the patient is taking, or plans to take, any prescription or over-the-counter drugs, because there is a potential for interactions <span class="Italics">[see </span><span class="Italics"><a href="#S7">Drug Interactions (7)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>Advise patients to avoid alcohol while taking RISPERDAL<span class="Sup">®</span><span class="Italics"> [see </span><span class="Italics"><a href="#S7.2">Drug Interactions (7.2)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>Inform patients with <span class="product-label-link" type="condition" conceptid="432872" conceptname="Phenylketonuria">Phenylketonuria</span> and caregivers that RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablets contain phenylalanine. Phenylalanine is a component of aspartame. Each 4 mg RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablet contains 0.84 mg phenylalanine; each 3 mg RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablet contains 0.63 mg phenylalanine; each 2 mg RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablet contains 0.42 mg phenylalanine; each 1 mg RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablet contains 0.28 mg phenylalanine; and each 0.5 mg RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablet contains 0.14 mg phenylalanine <span class="Italics">[see<a href="#S5.14"> Warnings and Precautions (5.14)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>Inform patients and caregivers that treatment with RISPERDAL<span class="Sup">®</span> can be associated with <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span><span class="Italics">[see<a href="#S5.5"> Warnings and Precautions (5.5)</a>]</span>.</p>
<p>
 
</p>
<p></p>
<p>Inform patients and caregivers about the risk of <span class="product-label-link" type="condition" conceptid="4010823" conceptname="Tardive dyskinesia">tardive dyskinesia</span> <span class="Italics">[see<a href="#S5.4"> Warnings and Precautions (5.4)</a>]</span>.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p><span class="Underline">RISPERDAL</span><span class="Underline"><span class="Sup">®</span> Tablets</span><br>Active ingredient is made in Ireland<br>Finished product is manufactured by:<br>Janssen Ortho, LLC<br>Gurabo, Puerto Rico 00778</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-18"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p><span class="Underline">RISPERDAL</span><span class="Underline"><span class="Sup">®</span> Oral Solution</span><br>Active ingredient is made in Belgium<br>Finished product is manufactured by:<br>Janssen Pharmaceutica NV<br>Beerse, Belgium</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-19"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p><span class="Underline">RISPERDAL</span><span class="Underline"><span class="Sup">®</span> M-TAB</span><span class="Underline"><span class="Sup">®</span> Orally Disintegrating Tablets</span><br>Active ingredient is made in Ireland<br>Finished product is manufactured by:<br>Janssen Ortho, LLC<br>Gurabo, Puerto Rico 00778</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-20"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p>RISPERDAL<span class="Sup">®</span> Tablets, RISPERDAL<span class="Sup">®</span> M-TAB<span class="Sup">®</span> Orally Disintegrating Tablets, and RISPERDAL<span class="Sup">®</span> Oral Solution are manufactured for:<br>Janssen Pharmaceuticals, Inc.<br>Titusville, NJ 08560</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-21"></a><p></p>
<h1>SPL UNCLASSIFIED</h1>
<p class="First"></p>
<p>Revised August 2012<br><span class="Sup">©</span> Janssen Pharmaceuticals, Inc. 2007</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-22"></a><p></p>
<h1>SPL PATIENT PACKAGE INSERT</h1>
<p class="First"></p>
<p><span class="Bold">USING YOUR RISPERDAL<span class="Sup">®</span> (risperidone) DISPENSING-PIPETTE AND BOTTLE</span></p>
<p><span class="Bold">NDC 50458-305-03 30mL</span></p>
<p><span class="Bold">RISPERDAL<span class="Sup">®</span><br>(risperidone) oral solution</span></p>
<p><span class="Bold">1mg/mL</span></p>
<p><span class="Bold">Each 1mL contains: 1mg of risperidone in an aqueous solution.</span></p>
<p><span class="Bold">Use this product as indicated below, unless directed otherwise by your Physician.</span></p>
<p><span class="Bold">IMPORTANT: Please read these instructions before using RISPERDAL<span class="Sup">®</span> (risperidone) oral solution.</span></p>
<table width="100%">
<col align="left" span="1" valign="top" width="5%">
<col align="left" span="1" valign="top" width="45%">
<col align="center" span="1" valign="top" width="50%">
<tbody class="Headless">
<tr class="First">
<td align="left"></td>
<td align="left">1.<span class="Bold">Push the plastic screw-cap on the bottle down while turning it counter-clockwise. Remove the unscrewed cap (see<a href="#fig1"> Figure 1</a>).</span>
</td>
<td align="center"><p class="First"><a name="fig1"></a><span class="Bold">Figure 1.</span><br><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ccb70f90-9ef1-4eac-925f-0178cacdac6b&amp;name=MM2.jpg"></p></td>
</tr>
<tr>
<td align="left"></td>
<td align="left">2.<span class="Bold">Insert the dispensing-pipette fully into the bottle (see<a href="#fig2"> Figure 2</a>).</span>
</td>
<td align="center"><p class="First"><a name="fig2"></a><span class="Bold">Figure 2.</span><br><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ccb70f90-9ef1-4eac-925f-0178cacdac6b&amp;name=MM3.jpg"></p></td>
</tr>
<tr>
<td align="left"></td>
<td align="left">3.<span class="Bold">While holding the outer barrel of the pipette, pull the plunger up to the level (see markings on side) that equals the dosage prescribed by your physician (see<a href="#fig3"> Figure 3</a>).</span>
</td>
<td align="center"><p class="First"><a name="fig3"></a><span class="Bold">Figure 3.</span><br><img alt="MM4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ccb70f90-9ef1-4eac-925f-0178cacdac6b&amp;name=MM4.jpg"></p></td>
</tr>
<tr>
<td align="left"></td>
<td align="left">4.<span class="Bold">Holding the outer barrel of the pipette, remove the entire pipette from the bottle, being careful not to depress the plunger prematurely (see<a href="#fig4"> Figure 4</a>).</span>
</td>
<td align="center"><p class="First"><a name="fig4"></a><span class="Bold">Figure 4.</span><br><img alt="MM5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ccb70f90-9ef1-4eac-925f-0178cacdac6b&amp;name=MM5.jpg"></p></td>
</tr>
<tr>
<td align="left"></td>
<td align="left">5.<span class="Bold">Empty the entire contents of the pipette into 3–4 ounces (100mL) of a beverage by pushing the plunger down inside the pipette barrel. Stir the mixture thoroughly before consuming. RISPERDAL<span class="Sup">®</span> is compatible with water, coffee, orange juice, or low-fat milk: IT IS NOT COMPATIBLE with cola or tea.</span>
</td>
<td align="center"></td>
</tr>
<tr>
<td align="left"></td>
<td align="left">6.<span class="Bold">Replace the plastic cap on the bottle by screwing it clockwise; rinse the empty dispensing-pipette with water. </span>
</td>
<td align="center"></td>
</tr>
<tr>
<td align="left">
<span class="Bold">DOSAGE: </span>For information about the use of<span class="Bold"> RISPERDAL<span class="Sup">®</span></span> (risperidone), please see accompanying<span class="Bold"> Package Insert</span>.<br> </td>
<td align="left"></td>
</tr>
<tr class="Last">
<td align="left">
<span class="Bold">STORAGE: </span>Store bottle at controlled room temperature (59°–77°F/15°–25°C) away from children; avoid freezing and protect from light.<br> </td>
<td align="left"></td>
</tr>
</tbody>
</table>
<p>Manufactured by:<br>Janssen Pharmaceutica N.V.<br>Beerse, Belgium</p>
<p>Manufactured for:<br>Janssen Pharmaceuticals, Inc.<br>Titusville, NJ, United States 08560</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-23"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: RISPERDAL </p>
<p><br></p>
<p>GENERIC: risperidone</p>
<p><br></p>
<p>DOSAGE: TABLET</p>
<p><br></p>
<p>ADMINSTRATION: ORAL</p>
<p><br></p>
<p>NDC: 52125-285-02</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul><li>risperidone 0.5mg in 1</li></ul>
<p><br></p>
<p>INACTIVE INGREDIENT(S):</p>
<ul>
<li>ferric oxide red</li>
<li>starch, corn</li>
<li>sodium lauryl sulfate</li>
<li>talc</li>
<li>titanium dioxide</li>
<li>propylene glycol</li>
<li>anhydrous lactose</li>
<li>hypromelloses</li>
<li>cellulose, microcrystalline</li>
<li>magnesium stearate</li>
<li>silicon dioxide</li>
</ul>
<p><br></p>
<p>COLOR: brown</p>
<p><br></p>
<p>SHAPE: OVAL</p>
<p><br></p>
<p>SCORE: No score</p>
<p><br></p>
<p>SIZE: 9 mm</p>
<p><br></p>
<p>IMPRINT: Ris;0;5;JANSSEN</p>
<p><br></p>
<p>PACKAGING: 30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</p>
<p><br></p>
<p><br></p>
<p><img alt="MM6" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ccb70f90-9ef1-4eac-925f-0178cacdac6b&amp;name=MM6.jpg"></p>
<p><img alt="MM7" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ccb70f90-9ef1-4eac-925f-0178cacdac6b&amp;name=MM7.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RISPERDAL 		
					</strong><br><span class="contentTableReg">risperidone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52125-285(NDC:50458-302)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>risperidone</strong> (RISPERIDONE) </td>
<td class="formItem">risperidone</td>
<td class="formItem">0.5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>anhydrous lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>silicon dioxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">brown</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (TABLET) </td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Ris;0;5;JANSSEN</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52125-285-02</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020272</td>
<td class="formItem">05/06/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>15e4f23d-84c7-438a-b53e-9149e63d0f36</div>
<div>Set id: ccb70f90-9ef1-4eac-925f-0178cacdac6b</div>
<div>Version: 1</div>
<div>Effective Time: 20130506</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
